Formulari Ubat ubatan kkm

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY monotherapy or in or 50 mg once weekly have combination with also been used successfully). methotrexate in patient’s Maintenance dose: 50 mg inadequate response to SC once weekly. Paediatric methotrexate alone. dose (2 to 17 years): Juvenile iv) Active ankylosing idiopathic arthritis; 0.8 mg/kg spondylitis in adults (max. 25 mg/dose) SC once v) Moderate to severe plaque weekly for once-weekly psoriasis who failed to dosing or 0.4 mg/kg (max. 25 respond to, or who have a mg/dose) SC twice weekly contraindication to, or are (individual doses should be intolerant to other systemic separated by 72 to 96 hours) therapy including for twice-weekly dosing. cyclosporine, methotrexate or PUVA i) Moderately to severe rheumatoid arthritis as Adult & geriatric dose: monotherapy or in Rheumatoid arthritis, combination with psoriatic arthritis, ankylosing methotrexate in patients with spondylitis; 50 mg SC once- inadequate response to weekly for once-weekly methotrexate alone. dosing or 25 mg SC twice ii) Active polyarticular-course weekly (individual doses juvenile idiopathic arthritis in should be separated by 72 to children 2-17 years with 96 hours) for twice-weekly inadequate response to, or dosing. Plaque psoriasis; who have proved intolerant of Initial: 50 mg SC twice methotrexate. weekly, 72 to 96 hours apart;578 Etanercept 50 mg Injection L04AB01000P4002X A* iii) Psoriatic arthritis as maintain initial dose for 3 X monotherapy or in months (starting doses of 25 combination with or 50 mg once weekly have methotrexate in patient’s also been used successfully). inadequate response to Maintenance dose: 50 mg methotrexate alone. SC once weekly. Paediatric iv) Active ankylosing dose (2 to 17 years): Juvenile spondylitis in adults idiopathic arthritis; 0.8 mg/kg v) Moderate to severe plaque (max. 25 mg/dose) SC once psoriasis who failed to weekly for once-weekly respond to, or who have a dosing or 0.4 mg/kg (max. 25 contraindication to, or are mg/dose) SC twice weekly intolerant to other systemic (individual doses should be therapy including separated by 72 to 96 hours) cyclosporine, methotrexate or for twice-weekly dosing. PUVA Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg579 Ethambutol HCl 200 mg J04AK02110T1001X B Tuberculosis biweekly (max2000mg). Tablet X Children: 15-25mg/kg daily or 50 mg/kg twice weekly. Adult: 15-25mg/kg daily (max580 Ethambutol HCl 400 mg J04AK02110T1002X B Tuberculosis 1200mg) or 50mg/kg Tablet X biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.581 Ether Solvent N01AA01000L9901X C To remove adhesive plaster Dose depending on the route X from the skin and procedureUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 101 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE G03AA12954T1002X CATEGORY582 Ethinylestradiol 20 mcg & i) Oral contraception 1 tab daily for 28 consecutive Drospirenone 3 mg Tablet X A* ii) Treatment of acne vulgaris days starting on 1st day of in women seeking oral menstrual bleeding. contraception. iii) Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. 1 tablet to be taken daily for 21 executive days starting on583 Ethinylestradiol 20 mcg & G03AA10954T1001X A/KK Oral contraception the first day of menses. Each Gestodene 75 mcg Tablet X subsequent pack is started after a 7 days tablet free interval. i) Prevention of pregnancy ii) Treatment of moderate acne vulgaris not controlled Beginning on day 1 of cycle, by conventional therapy (e.g 1 tablet daily for 21 days Ethinylestradiol 20 mcg & G03AA07954T1002X A/KK topical preparations and oral followed by 7 tablet-free584 Levonorgestrel 100 mcg X antibiotics) in post- days. menarchal, premenopausal Tablet women more than or 14 years who accept contraception.585 Ethionamide 250 mg Tablet J04AD03000T1001X A* As second-line therapy in the ADULT: 15-20mg/kg daily, in X treatment of Multi Drug divided doses if necessary; maximum dose 1g/day. Resistant Tuberculosis only CHILD: 10-20mg/kg in 2-3 divided doses or in combination with other 15mg/kg/24hrs as a single efficacious agents and only daily dose. when therapy with isoniazid, rifampicin, or other first-line agents has failed. ADULT: Initially, 500 mg daily. Increased by 250 mg at intervals of 4-7 days to usual dose of 1-1.5 g daily. Maximum: Up to 2 g, under strict supervision. CHILD: Ethosuximide 250 mg/5 ml Greater than or equal to 6 Syrup N03AD01000L9001X years: Same as adult dose;586 X B Absence seizures less than 6 years: Initially, 250 mg daily. Increased gradually to usual dose of 20 mg/kg daily. Maximum: Children greater than or equal to 6 years: Same as adult dose; less than 6 years: Up to 1 g For minor surgical587 Ethyl Chloride 100ml Spray N01BX01000A4001X C procedures including lancing Spray to affected area at a X boils, incision and drainage distance of about 30cm until of small abscesses, pain due a fine white film is produced to athletic injuries and painUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 102 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY due to injection administration588 Etomidate 20 mg/10 ml N01AX07000P3001X A* Induction of general Adult: 300 mcg/kg given Injection X anaesthesia for slowly over 30-60 seconds haemodynamically unstable into a large vein in the arm.589 Etonogestrel 68 mg Implant G03AC08000P1001 A/KK patients Child: Up to 30% more than XX the standard adult dose. Contraception Elderly: 150-200 mcg/kg,590 Etoposide 100 mg/5 ml L01CB01000P3001X A* subsequently adjusted Injection X i) For treatment of children according to effects. with solid tumours, juvenile591 Etoposide 50mg capsule L01CB01000C1003X A* myelomonocytic leukemia A single implant inserted X (JMML) and Langerhan cell subdermally and can be left histiocytosis in place for three years. The592 Etoricoxib 120 mg Tablet M01AH05000T1002 A* ii) Leukaemia, lymphoma implant can be removed at XX iii) Testicular cancer, lung any time but not later than cancer, gestational three years after the date of593 Etoricoxib 60 mg Tablet M01AH05000T1003 A* trophoblastic disease, gastric insertion. XX cancer, sarcoma i) CHILD: 60-120 mg/m2/day Treatment of small cell lung by IV for 3 - 5 days every 3 - cancer and malignant 6 weeks depending on lymphomas protocols ii) Maintenance or palliative i) Acute and chronic chemotherapy for elderly treatment of signs and acute myeloid leukemia, symptoms of osteoarthritis consolidation therapy for (OA) and rheumatoid arthritis acute lymphoblastic (RA) leukemia, stem cell ii) Acute gouty arthritis mobilization (Refer to iii) Acute pain protocol) iii) 100 mg/m2 by IV every i) Acute and chronic other day for 3 doses treatment of signs and repeated every 3-4 weeks symptoms of osteoarthritis Normal adult dose is 175mg- 200mg daily for 5 consecutive days orally, followed by recession (withdrawal) interval of 3 weeks. Repeat administration as necessary. Increase or reduce dose as appropriate, according to the particular disease or symptoms. i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment) i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritisUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 103 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY594 Etoricoxib 90 mg Tablet M01AH05000T1001 (OA) and rheumatoid arthritis and acute pain: 120 mg once XX A* (RA) daily (Given the exposure to595 Everolimus 0.25mg tablet ii) Acute gouty arthritis COX-2 inhibitors, doctors are L04AA18000T1001X A* iii) Acute pain advised to use the lowest596 Everolimus 0.75mg tablet X effective dose for the shortest A* i) Acute and chronic possible duration of597 Exemestane 25 mg Tablet L04AA18000T1003X A* treatment of signs and treatment) X A* symptoms of osteoarthritis i) OA: 60 mg once daily. RA:598 Ezetimibe 10 mg & A* (OA) and rheumatoid arthritis 90 mg once daily Simvastatin 20 mg Tablet L02BG06000T1001X (RA) ii & iii) Acute gouty arthritis X ii) Acute gouty arthritis and acute pain: 120 mg once599 Ezetimibe 10 mg Tablet iii) Acute pain daily (Given the exposure to C10BA02000T1001X COX-2 inhibitors, doctors are X Indicated for the prophylaxis advised to use the lowest of organ rejection in adult effective dose for the shortest C10AX09000T1001X patients at low to moderate possible duration of X immunological risk receiving treatment) an allogeneic renal or cardiac An initial dose regimen of transplant in combination 0.75 mg b.i.d., which is with ciclosporin for recommended for the general microemulsion and kidney and heart transplant corticosteroids. population. The daily dose of Indicated for the prophylaxis everolimus should always be of organ rejection in adult given orally in two divided patients at low to moderate doses (b.i.d.). immunological risk receiving an allogeneic renal or cardiac An initial dose regimen of transplant in combination 0.75 mg b.i.d., which is with ciclosporin for recommended for the general microemulsion and kidney and heart transplant corticosteroids. population. The daily dose of Treatment of post- everolimus should always be menopausal women with given orally in two divided advanced breast cancer doses (b.i.d.). whose disease has progressed following 25 mg once daily tamoxifen and non-steroidal aromatase inhibitors Usual starting dose: 10/20 mg/day Primary hypercholesterolemia 10 mg once daily. Not recommended for children i) Co-administration with less than 10 years old statins for patients who have chronic heart disease or are chronic heart disease equivalent or familial hypercholesterolaemia with target LDL-C not achieved by maximum dose of statins ii) Monotherapy in patients with documented biochemical intolerance to statinsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 104 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY600 Ezetimibe 10mg/ C10BA02000T1003X A* Primary Usual starting dose: 10/20 Simvastatin 40mg Tablet X hypercholesterolemia mg/day Dose varies according to the patient and the circumstances of the bleeding. i) Mild haemorrhage: initial dose of 30 units/kg body601 Factor IX Injection B02BD04000P9901X A Prevention and control of weight. X bleeding in patients with ii) Moderate haemorrhage: factor IX deficiency due to initial dose of 50 units/kg haemophilia B iii) Major haemorrhage/surgery: Initial dose of 75 - 100 units/kg. Half of these doses may be repeated after 18-24 hrs if necessary. Amount and frequency of administration should be calculated on an individual patient basis. Individual dosage requirements can Factor IX, Factor II, Factor B02BD01000P4001X A* i) Treatment and only be identified on the602 VII and Factor X In X perioperative prophylaxis of basis of regular bleeding in acquired determinations of the Combination Injection deficiency of the prothrombin individual plasma levels of complex coagulation factors, the coagulation factors of such as deficiency caused by interest or on the global tests treatment with vitamin K of the prothrombin complex antagonists, or in case of levels (INR, Quick's test) and overdose of vitamin K a continuous monitoring of antagonists, when rapid the clinical condition of the correction of the deficiency is patient. An approximate required. ii) Treatment and calculation is as follows: perioperative prophylaxis of Required dose (IU) = body bleeding in congenital weight (kg) x desired factor deficiency of any of the rise (IU/dl or % of normal) x vitamin K dependent reciprocal of the estimated coagulation factors only if recovery, i.e. Factor II = 53 purified specific coagulation Factor VII = 59 Factor IX = factor product is not 77 Factor X = 56 As product available. may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation. Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-603 Factor VIIa (Recombinant) B02BD08000P4005X A* Treatment of bleeding 5 minutes, followed by 3-6 eptacog alfa (activated) 100 X episodes and prevention of KIU (60-120 mcg)/kg body KIU (2 mg) Injection excessive bleeding in weight depending on type & connection with surgery in severity of haemorrhage or patients with inherited or surgery performed. Dosing acquired haemophilia with interval: initially 2-3 hour to inhibitors to coagulation obtain haemostasis and until factors VIII or IX clinically improved. If continued therapy is needed,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 105 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY dose interval can be increased successively to every 4, 6, 8 or 12 hours Factor VIIa (Recombinant) B02BD08000P4004X A* Treatment of bleeding Initially 4.5 KIU (90 mcg)/kg604 eptacog alfa (activated) 50 X episodes and prevention of body weight IV bolus over 2- excessive bleeding in 5 minutes, followed by 3-6 KIU (1 mg) Injection connection with surgery in KIU (60-120 mcg)/kg body patients with inherited or weight depending on type & Factor VIII (Human blood B02BD06000P4002X A* acquired haemophilia with severity of haemorrhage or605 coagulation factor) & Von X inhibitors to coagulation surgery performed. Dosing factors VIII or IX interval: initially 2-3 hour to Willebrand factor Injection obtain haemostasis and until i) The treatment and clinically improved. If prophylaxis of haemorrhage continued therapy is needed, or surgical bleeding in Von dose interval can be Willebrand Disease (VWD) increased successively to when 1-deamino-8-D- every 4, 6, 8 or 12 hours arginine vasopressin (desmopressin, DDAVP) i. Von Willebrand Disease: treatment alone is ineffective Spontaneous Bleeding or contraindicated. ii)The Episodes: Initially, factor VIII treatment and prophylaxis of 12.5-25 IU/kg and ristocetin bleeding associated with cofactor 25-50 IU/kg followed factor VIII deficiency due to by factor VIII 12.5 IU/kg and haemophilia A. ristocetin cofactor 25 IU/kg subsequently every 12-24 hrs. Minor Surgery: Factor VIII 30 IU/kg and ristocetin cofactor 60 IU/kg daily. Major Surgery: Initially, factor VIII 30-40 IU/kg and ristocetin cofactor 60-80 IU/kg followed by factor VIII 15-30 IU/kg and ristocetin cofactor 30-60 IU/kg subsequently every 12- 24 hrs. Prophylaxis: Factor VIII 12.5-20 IU/kg and ristocetin cofactor 25-40 IU/kg 3 times weekly. ii. Hemophilia A therapy: Minor haemorrage: 10-15 IU/kg every 12-24 hours. Moderate to severe haemorrhage: 15-40 IU/kg every 8 to 24 hours. Minor surgery: Loading dose 20-30 IU/kg, maintenance dose 15- 30 IU/kg. Major surgery: Loading dose 40-50 IU/kg, maintenance dose 10-40 IU/kg. Prophylaxis: 25-40 IU/kg three times weekly AsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 106 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation. Factor VIII (Recombinant) B02BD02000P4001X A* i) Control and prevention of The dosage and duration of606 Octocog Alfa 250 IU X bleeding episodes in adults treatment should be and children (0-16 years) individualised and taking into Injection with hemophilia A. account the severity of factor ii) Surgical prophylaxis in VIII deficiency, location and Factor VIII (Recombinant) B02BD02000P4002X A* adults and children with extent of bleeding and607 Octocog Alfa 500 IU X hemophilia A. patient's clinical condition. iii) Routine prophylactic Dose can be calculated by Injection treatment to reduce the using: frequency of bleeding i. Required dose (IU) = body episodes and the risk of joint weight (kg) x desired factor damage in children with no VIII rise (IU/dl or % of pre-existing joint damage. normal) x 0.5 (IU/kg) or Not indicated fot the ii. Expected factor VIII rise (% treatment of von willebrand's of normal) = 2 x (dose disease. administered)/ bodyweight (kg) Dose administered i) Control and prevention of should be titrated to patient's bleeding episodes in adults clinical response and children (0-16 years) with hemophilia A. The dosage and duration of ii) Surgical prophylaxis in treatment should be adults and children with individualised and taking into hemophilia A. account the severity of factor iii) Routine prophylactic VIII deficiency, location and treatment to reduce the extent of bleeding and frequency of bleeding patient's clinical condition. episodes and the risk of joint Dose can be calculated by damage in children with no using: pre-existing joint damage. i. Required dose (IU) = body Not indicated for the weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5 (IU/kg) or ii. Expected factor VIII rise (%Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 107 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY treatment of von willebrand's of normal) = 2 x (dose disease. administered)/ bodyweight (kg) Dose administered should be titrated to patient's clinical response.608 Factor VIII Inhibitor B02BD03000P4001X A i) Treatment and prophylaxis As a general guideline, a Bypassing Activity Injection X of hemorrhages in dose of 50 to 100IU/kg body hemophilia A and B patients weight is recommended, not609 Factor VIII Injection B02BD02999P9901X A with inhibitors. exceeding an individual dose X ii) Treatment and prophylaxis of 100IU/kg bw and a of hemorrhages in non- maximum daily dose of610 Fat Emulsion 10% for IV B05BA02000P6001X A hemophilic patients who have 200IU/kg bw. Infusion Injection X A developed inhibitors to Factors VIII, IX and XI. Dose varies according to the611 Fat Emulsion 20% for IV B05BA02000P6002X iii) Treatment of patients with patient and the Infusion Injection X acquired inhibitors to Factors circumstances of the X and XIII. bleeding. i) Mild to moderate: iv) In the combination with Usually a single dose of 10- Factor VIII concentrate for a 15units/kg. long-term therapy to achieve ii) More serious a complete and permanent haemorrhage/minor surgery: elimination of the Factor VIII Initially 15-25 units/kg inhibitor so as to allow for followed by 10-15 units/kg regular treatment with Factor every 8 - 12 hours if required VIII concentrate as in iii) Severe patients without inhibitor. haemorrhage/major surgery: Initial: 40 - 50 units/kg Prevention and control of followed by 20 - 25 units/kg bleeding in patients with every 8-12 hrs. factor VIII deficiency due to Dose to be individualised. classical haemophilia A ADULT usual lipid requirement 2-3 g/kg/day. Source of lipid in patients INFANT 0.5 - 1 g/kg/day needing IV nutrition Dose to be individualised. ADULT usual lipid Source of lipid in patients requirement 2-3 g/kg/day. needing IV nutrition INFANT 0.5-1 g/kg/dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 108 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE612 Felodipine 10 mg Tablet C08CA02000T1002X CATEGORY613 Felodipine 5 mg Tablet Hypertension Initiate at 5 mg once daily. X A/KK Usual dose, 5 - 10 mg once614 Fenofibrate 145 mg tablet C08CA02000T1001X A/KK Hypertension daily in the morning Initiate at 5 mg once daily.615 Fentanyl 12mcg/h X A/KK As second line therapy after Usual dose, 5 - 10 mg once Transdermal Patch failed gemfibrozil in patients: daily in the morning C10AB05000T1002X A* i) Hypercholesterolemia and616 Fentanyl 25 mcg/h X hypertriglyceridemia alone or 145mg once daily, with or Transdermal Patch A* combined [type IIa,IIb,III and without food N02AB03136M7005 V dysplipidemias] in patients617 Fentanyl 50 mcg/h XX A* unresponsive to dietary and ADULT and CHILD over 2 Transdermal Patch other non-pharmacological years previously treated with N02AB03136M7001 measures especially when a strong opioid analgesic, XX there is evidence of initial dose based on associated risk factors previous 24-hour opioid N02AB03136M7002 ii) Treatment of secondary requirement (consult product XX hyperlipoproteinemias if literature). If necessary dose hyperlipoprotenemia persists should be adjusted at 72- despite effective treatment of hour intervals in steps of 12- underlying disease 25 mcg/hr iii) Dyslipidemia in Type 2 Patients who have not Diabetes Mellitus previously received a strong As a second line drug in the opioid analgesic, initial dose, management of chronic one 25 mcg/hour patch to be severe cancer pain not replaced after 72 hours. responding to non-narcotic Patients who have received a analgesic. Not to be used in strong opioid analgesic, initial opiod naive patients.The use dose based on previous 24 is to be restricted to pain hours opioid requirement specialists, palliative (oral morphine sulphate 90 medicine specialists and mg over 24 hours = one 25 oncologists mcg/hour patch). Not recommended in children. As a second line drug in the Patients who have not management of chronic previously received a strong cancer pain. The use is to be opioid analgesic, initial dose, restricted to pain specialists, one 25 mcg/hour patch to be palliative medicine specialists replaced after 72 hours. and oncologists. Patients who have received a strong opioid analgesic, initial As a second line drug in the dose based on previous 24 management of chronic hours opioid requirement cancer pain. The use is to be (oral morphine sulphate 90 restricted to pain specialists, palliative medicine specialists and oncologistsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 109 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY mg over 24 hours = one 25 mcg/hour patch). Not recommended in children. Dose should be individualized according to age, body weight, physical status, underlying pathological conditions and type of surgery and anaesthesia. ADULT: Premedication: IM 50 - 100 mcg, 30 - 60 mins prior to surgery. Adjunct to general anaesthesia: Induction IV 50 Short duration analgesia - 100mcg, repeat 2 - 3 mins during pre-medication intervals until desired effect is Fentanyl Citrate 50 mcg/ml N01AH01136P3001 induction and maintenance of achieved. IV/IM 25 - 50mcg618 Injection XX A anaesthesia, and in the in elderly and poor risk immediate post-operative patients. Maintenance: IV/IM period. 25 - 50mcg. Adjunct to regional anaesthesia: IM/slow IV 50 - 100mcg when additinal analgesia is required. Post-operatively (recovery room): IM 50 - 100mcg for pain control, tachypnoea and emergency delirium. May be repeated in 1- 2 hours as needed. CHILD (2 - 12 years): Induction & maintenance: 2 - 3 mcg/kg. Ferric Ammonium Citrate B03AB06136L2101X C Prevention and treatment of CHILD up to 1 year 5 ml, 1 -619 800 mg/10 ml Paediatric X iron-deficiency anaemias 5 years 10 ml, taken well diluted with water Mixture Anemia due to iron deficiency, megaloblastic Ferrous controlled release anemia where there is an 500 mg, Vitamin B1, associated deficiency of Vitamin B2, Vitamin B6, Vitamin C and Vitamin B-620 Vitamin B12, Vitamin C, B03AE10903T1001X A/KK complex particularly in One tablet daily X pregnancy. In primary health Niacinamide, Calcium Pantothenate, Folic Acid clinic, the indication is 800 mcg Tablet restricted to anemia due to iron deficiency in pregnant women ONLY. Adult: Usual dose range: Up to 600 mg daily. May621 Ferrous Fumarate 200 mg B03AA02138T1001X C+ Prevention and treatment of increase up to 1.2 g daily if Tablet X iron-deficiency anaemias necessary. Child: As syrup containing 140 mg(45 mg iron)/5ml. Preterm neonate:Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 110 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 0.6-2.4 ml/kg daily; up to 6 years old: 2.5-5ml twice daily622 Filgrastim (G-CSF) 30 L03AA02000P3001X A* i) Reduction in the duration of i) Adult: SC or IV 5 MU/ml Injection X neutropenia and incidence of mcg/kg/day. Initiation: 24 - 72 febrile neutropenia in hours after chemotherapy.623 Filgrastim 30 MU in 0.5 ml L03AA02000P5001X A* cytotoxic chemotherapy for Duration: Until a clinically Injection X malignancy except chronic adequate neutrophil recovery myeloid leukemia and is achieved (absolute624 Finasteride 5 mg Tablet G04CB01000T1001 A* myelodysplastic syndrome neutrophil count of at least 1 XX ii) Haemopoeitic stem cell x 109/L on 2 consecutive transplantation (HSCT)/stem days)625 Fingolimod 0.5mg Capsule L04AA27110C1001X A* cell harvesting ii) Refer to protocol X i) Reduction in the duration of i) ADULT: 5 mcg/kg/day by neutropenia and incidence of SC or IV. Initiation: 24 - 72626 Flavoxate HCl 100 mg G04BD02110T1001 A febrile neutropenia in hours after chemotherapy. Tablet XX cytotoxic chemotherapy for Duration: Until a clinically malignancy except chronic adequate neutrophil recovery627 Flecainide Acetate 100 mg C01BC04122T1001X A* myeloid leukemia and is achieved (absolute Tablet X myelodysplastic syndrome neutrophil count of at least 1 ii) Haemopoeitic stem cell x 109/L on 2 consecutive transplantation (HSCT)/stem days) cell harvesting ii) Refer to protocol 5 mg a day as a single dose. Treatment and control of Clinical responses occur benign prostatic hyperplasia within 12 weeks - 6 months of initiation of therapy. Long- Treatment of patients with term administration is relapsing forms of multiple recommended for maximal sclerosis to reduce the response frequency of clinical exacerbations and to delay 0.5mg orally once daily the accumulation of physical disability ADULT: 200 mg 3 times Urinary frequency and daily. CHILD under 12 years incontinence, dysuria, not recommended urgency, bladder spasm due to catheterisation Ventricular arrhythmias: 100 i) Sustained monomorphic mg twice daily, maximum 400 ventricular tachycardias mg/day (usually reserved for ii) Preexcited atrial fibrillation rapid control or in heavily associated with Wolff- built patients), reduced after Parkinson White Syndrome 3 - 5 days if possible. iii) Reciprocating Atrio- Supraventricular arrhythmias: Ventricular tachycardias 50 mg twice daily, increased (AVT) associated with Wolff- if required to maximum of Parkinson White Syndrome 150 mg twice daily iv) Supraventricular tachycardias due to Intra- Atrio Ventricular Nodul ReentryUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 111 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Oropharyngeal candidiasis, i) Oropharyngeal candidiasis:628 Fluconazole 100 mg J02AC01000C1002X A atrophic oral candidiasis 50 - 100 mg daily for 7 - 14 Capsule X associated with dentures, days (Maximum 14 days) other candidal infections of except in severely629 Fluconazole 2 mg/ml J02AC01000P9901X A mucosa immunocompromised Injection X ii) Tinea pedis, corporis, patients, treatment can be cruris, versicolor and dermal continued for longer periods. candidiasis Atrophic oral candidiasis iii) Invasive candidal & associated with dentures: 50 cryptococcal infections mg daily for 14 days. Other (including meningitis) candidal infections of iv) Prevention of relapse of mucosa: 50 - 100 mg daily cryptococcal meningitis in for 14 - 30 days. CHILD: 3 - 6 AIDS patients after mg/kg on first day then 3 completion of primary mg/kg daily (every 72 hours therapy in NEONATE up to 2 weeks v) Prevention of fungal old, every 48 hours in infections in NEONATE 2 - 4 weeks old) immunocompromised ii) 50 mg daily for 2 - 4 patients considered at risk as weeks, maximum 6 weeks a consequence of HIV iii) 400 mg initially then 200 - infections or neutropenia 400 mg daily for 6 - 8 weeks. following cytotoxic CHILD: 6 - 12 mg/kg daily chemotherapy, radiotherapy (every 72 hours in NEONATE or bone marrow transplant up to 2 weeks old, every 48 hours in NEONATE 2 -4 i) Oropharyngeal candidiasis, weeks old) iv) 100 - 200 mg atrophic oral candidiasis daily associated with dentures, v) 50 - 400 mg daily. CHILD: other candidal infections of 3 - 12 mg/kg daily (every 72 mucosa hours in NEONATE up to 2 ii) Tinea pedis, corporis, weeks old, every 48 hours in cruris, versicolor and dermal NEONATE 2 - 4 weeks old) candidiasis i) 50 - 100 mg daily for 7 - 14 iii) Invasive candidal& days (Maximum 14 days) cryptococcal infections except in severely (including meningitis) immunocompromised iv) Prevention of relapse of patients, treatment can be cryptococcal meningitis in continued for longer periods. AIDS patients after Atrophic oral candidiasis completion of primary associated with dentures: 50 therapy mg daily for 14 days. Other v) Prevention of fungal candidal infections of infections in mucosa: 50 - 100 mg daily immunocompromised for 14 - 30 days. CHILD: 3 - 6 patients considered at risk as mg/kg on first day then 3 a consequence of HIV mg/kg daily (every 72 hours infections or neutropenia in NEONATE up to 2 weeks following cytotoxic old, every 48 hours in chemotherapy, radiotherapy NEONATE 2 - 4 weeks old) or bone marrow transplant ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeksUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6-12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 112 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) i) Oropharyngeal candidiasis: 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely i) Oropharyngeal candidiasis, immunocompromised atrophic oral candidiasis patients, treatment can be associated with dentures, continued for longer periods. other candidal infections of Atrophic oral candidiasis mucosa associated with dentures: 50 ii) Tinea pedis, corporis, mg daily for 14 days. Other cruris, versicolor and dermal candidal infections of candidiasis mucosa: 50 - 100 mg daily iii) Invasive candidal & for 14 - 30 days. CHILD: 3 - 6 cryptococcal infections mg/kg on first day then 3 (including meningitis) mg/kg daily (every 72 hours630 Fluconazole 50 mg Capsule J02AC01000C1001X A iv) Prevention of relapse of in NEONATE up to 2 weeks X cryptococcal meningitis in old, every 48 hours in AIDS patients after NEONATE 2 - 4 weeks old) completion of primary ii) 50 mg daily for 2 - 4 therapy weeks, maximum 6 weeks v) Prevention of fungal iii) 400 mg initially then 200 - infections in 400 mg daily for 6 - 8 weeks. immunocompromised CHILD: 6 - 12 mg/kg daily patients considered at risk as (every 72 hours in NEONATE a consequence of HIV up to 2 weeks old, every 48 infections or neutropenia hours in NEONATE 2 -4 following cytotoxic weeks old) chemotherapy, radiotherapy iv) 100 - 200 mg daily or bone marrow transplant v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ADULT: 100 - 200 mg/kg631 Flucytosine 2.5 g/250 ml J02AX01000P9901X A* Treatment of systemic fungal daily in 4 divided doses by IV Injection X infection infusion over 20 - 40 minutes not more than 7 days632 Flucytosine 500 mg Tablet J02AX01000T1001X A* Only for the treatment of ADULT: 50 - 150 mg/kg/day X fungal meningitis in 4 divided doses633 Fludarabine Phosphate 10 L01BB05162T1001X A* B-cell chronic lymphocytic 40 mg /m2 given daily for 5 mg Tablet X leukemia who have not consecutive days every 28 responded to or whose days. Courses may be disease had progressed repeated every 28 days, during or after treatment with usually for up to 6 cycles. at least one standard Duration of treatment alkylating-agent containing depends on treatment regimen success and tolerability of the drugUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 113 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 25 mg/m2 daily for 5 consecutive days every 28634 Fludarabine Phosphate 50 L01BB05162P4001X A* B-cell chronic lymphocytic days. May be administered mg Injection X leukaemia who have not up to the achievement of a responded to or whose maximal response (usually 6 disease had progressed cycles) and then the drug during or after treatment with should be discontinued. at least one standard Reduce dose by up to 50% in alkylating-agent containing patients with mild to regimen moderate renal impairment (30-70ml/min) As an adjunct to Adrenocorticoid insufficiency glucocorticoids in the (chronic): ADULT 1 tablet Fludrocortisone Acetate 0.1 H02AA02122T1001X management of primary daily. Salt-losing635 mg Tablet X A adrenocortical insufficiency in adrenogenital syndrome: Addison's disease and ADULT 1 - 2 tablets daily. treatment of salt-losing CHILD and INFANT 0.5 - 1 adrenogenital syndrome tablet daily i) Initial, 0.2 mg IV over 30 seconds; if desired level of consciousness not obtained after an additional 30 seconds, give dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV over 30 seconds may be given at 1- minutes intervals if needed to maximum total dose of 3 mg; patients with only partial response to 3 mg may require additional slow titration to a total dose of 5 mg; if no response 5 minutes after receiving total dose of 5636 Flumazenil 0.1 mg/ml V03AB25000P3001X B i) Diagnosis and/or mg, overdose is unlikely to Injection X management of be benzodiazepine and benzodiazepine overdose further treatment with due to self-poisoning or flumazenil will not help accidental overdose ii) 0.2 mg IV over 15 ii) Reversal of sedation seconds; if desired level of following anaesthesia with consciousness is not benzodiazepine obtained after waiting 45 seconds, a second dose of 0.2 mg IV may be given and repeated at 60-seconds intervals as needed (up to a maximum of 4 additional times) to a maximum total dose of 1 mg; most patients respond to doses of 0.6 to 1 mg; in the event of resedation, repeated doses may be given at 20-minutes intervals if needed; for repeat treatment, no more than 1 mg (given as 0.5 mg/minute) should be given at any oneUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 114 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY time and no more than 3 mg should be given in any one hour637 Flunarizine HCl 5 mg N07CA03110C1001 B i) Migraine prophylaxis i) ADULT: 5 - 10 mg daily Capsule XX ii) Maintenance treatment of preferably at night. ELDERLY vestibular disturbances and more than 65 years: 5 mg at638 Fluorescein 1 mg S01JA01520M9901X B of cerebral and peripheral night. Maintenance 5-day Ophthalmic Strip X A disorders treatment at the same daily A* dose639 Fluorescein Sodium 10% in S01JA01520P3001X Diagnostic fluorescein ii) 5 - 10 mg at night. If no 5 ml Injection X angiography or angioscopy of improvement after 1 month, the fundus and of the iris discontinue treatment640 Fluorometholone 0.1% S01BA07000D2001X vasculature Moisten tip with tear fluid Ophthalmic Suspension X from lower fornix, sterile Diagnostic fluorescein water or ophthalmic solution641 Fluorouracil 1 g/20 ml L01BC02000P4002X A* angiography or angioscopy of and gently stroke across the Injection X the fundus and of the iris conjunctiva vasculature Treatment of steroid 500 mg IV responsive ocular inflammation 1-2 drops qds. During the initial 24-48 hr, dose may be Cancers of gastro-intestinal increased to 2 drops 2 hrly. tract, breast and pancreas, 500 - 600 mg/m2 IV in head and neck. combination with other Ophtalmological indication: cytotoxic agents, repeated trabeculectomy every 3 weeks or 300 - 450 mg/m2 IV slow bolus daily for 5 days in combination with biological response modifiers, repeated every 4 weeks or 3000 - 3750 mg/m2 as a continuous infusion over 5 days in combination with aUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 115 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY platinum compound every 3 to 4 weeks642 Fluorouracil 100 mg Tablet L01BC02000T1001X A Colorectal cancer 15 mg/kg (max: 1 g/day), X may be given once weekly Cancers of gastro-intestinal for maintenance. Max: 1643 Fluorouracil 50 mg / ml in 5 L01BC02000P4001X A* tract, breast and pancreas, g/week. ml Injection X head and neck. Intravenous Infusion: 15 Ophtalmological indication: mg/kg bodyweight (to a644 Fluoxetine HCl 20 mg N06AB03110C1001 A trabeculectomy maximum of 1 g daily) diluted Capsule XX in 300-500mL of 5% glucose i) Depression given over a period of 4645 Flupenthixol Decanoate N05AF01135P2001X B ii) Obsessive-compulsive hours. 12 mg/kg bodyweight 20mg/ml lnjection X disorder daily for 3 consecutive days. Providing there are no signs Chronic psychoses of toxic effects, the patient may then be given 6mg/kgUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) I.V. on the 5th, 7th and 9th days. If after the 9th day there is still no sign of toxicity, the patient may be placed on maintenance therapy. Maintenance Therapy: 5 - 10mg/kg bodyweight by I.V. injection once a week. i) 20 mg once daily increased after 3 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily max 80 mg once daily (ELDERLY max 60 mg once daily). ii) Initially 20 mg once daily increased after 2 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily, max 80 mg (ELDERLY max 60 mg) once daily, discontinue if no improvement within 10 weeks. CHILD and ADOLESCENT under 18 years are not recommended By deep IM, initial test dose of 5-20 mg, then after at least 7 days. 20 - 40 mg repeated at intervals of 2 - 4 weeks. Maximum 400 mg weekly. Usual maintenance dose 50 mg every 4 weeks to 300 mg every 2 weeks. ELDERLY, 116 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY initially quarter to half adult dose. CHILD not recommended. Deep IM recommended. Not for IV use By deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after 4-7 days 12.5 mg-646 Fluphenazine Decanoate 25 N05AB02135P3001X B Long term management of 100 mg repeated at intervals psychotic disorders of 14-35 days, adjusted mg/ml Injection X according to response. CHILD not recommended647 Flutamide 250 mg Tablet L02BB01000T1001X A* Metastatic prostatic 250 mg 3 times daily X carcinoma Treatment of nasal symptoms (rhinorrhea, nasal Adults/Adolescents (≥12 congestion, nasal itching and years) : 1-2 sprays (27.5 Fluticasone Furoate 27.5 R01AD08139A4101 sneezing) and ocular mcg/spray) in each nostril mcg/dose Nasal Spray XX648 A* symptoms (itching/burning, once daily. Children (2-11 tearing/watering, and years) : 1-2 sprays (27.5 redness of the eye) of mcg/spray) in each nostril seasonal and perennial once daily allergic rhinitis. ADULT and CHILD more than 16 years i) Mild asthma : 100 mcg - 250 mcg twice daily ii) Moderate asthma : 250 - 500 mcg twice daily iii) Severe asthma : 500 mcg - 1000 mcg twice daily. Prophylactic treatment for Alternatively, the starting Fluticasone Propionate 125 R03BA05133A2101X asthma dose of fluticasone649 mcg/dose Inhaler X B dipropionate may be gauged at half the total daily dose of beclomethasone dipropionate or equivalent administered by inhalation. CHILD 4 - 11 years, 50 mcg twice daily (maximum 100 mcg twice daily), CHILD 1-4 years, 50- 100mcg microgram twice daily For depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in650 Fluvoxamine 100 mg Tablet N06AB08253T1002X B Depression divided doses); usual X maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommendedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 117 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY For depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in651 Fluvoxamine 50 mg Tablet N06AB08253T1001X B Depressive disorder divided doses); usual X maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended i) ADULT initially 10-20mg mg daily for 14 days or until652 Folic Acid 5 mg Tablet B03BB01000T1001X C+ i) For the prevention and haematopoietic response X treatment of folate deficiency obtained. Daily maintenance: states 2.5 mg-10mg .CHILD up to 1 ii) For the prevention of year:250 mcg/kg daily; 1 to 5 neural tube defect in the years:2.5mg/day;6-12 years: foetus 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester i) Infertility treatment in653 Follitropin Alpha G03GA05000P3002 A* anovulatory women who i) 75 - 150 IU daily, should (Recombinant Human FSH) XX have been unresponsive to commence within the first 7 300 IU/0.5 ml Injection treatment with clomiphene days of the menstrual cycle citrate and increased by 37.5 IU or ii) Stimulation of follicular 75 IU at 7 or 14 days interval. development for intra-uterine Max daily dose 225 IU cycles ii) 150 - 225 IU daily iii) Stimulation of follicular commencing on days 2 or 3 development in assisted of the cycle. Max daily dose reproductive technology in 450 IU the management of infertility i) Infertility treatment in anovulatory women who i) 75 - 150 IU daily, should have been unresponsive to commence within the first 7 treatment with clomiphene days of the menstrual cycle Follitropin Alpha citrate and increased by 37.5 IU or (Recombinant Human FSH)654 75 IU Injection G03GA05000P3001 A* ii) Stimulation of follicular 75 IU at 7 or 14 days interval. XX development for intra-uterine Max daily dose 225 IU cycles ii) 150 - 225 IU daily iii) Stimulation of follicular commencing on days 2 or 3 development in assisted of the cycle. Max daily dose reproductive technology in 450 IU the management of infertility Infertility treatment in655 Follitropin Beta G03GA06000P3002 A* anovulatory women who To be individualized. Give in (Recombinant Human FSH) XX have been unresponsive to multiples of 50 IU. Starting 300 IU Injection treatment with clomiphene dose can be 50 IU - 200 IU citrate. Stimulation of daily. It can be a step-up follicular development for regime or a step-down, intra-uterine insemination depending on the protocol cycles and assisted and the ovarian response reproductive technology in the management of infertility.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 118 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Infertility treatment in anovulatory women who656 Follitropin Beta G03GA06000P3001 A* have been unresponsive to To be individualized. Give in (Recombinant Human FSH) XX treatment with clomiphene multiples of 50 IU. Starting 50 IU Injection citrate. Stimulation of dose can be 50 IU - 200 IU follicular development for daily. It can be a step-up intra-uterine insemination regime or a step-down, cycles and assisted depending on the protocol reproductive technology in and the ovarian response the management of infertility. The recommended dose to be administered by SC injection once daily is: 5mg for body weight less than 50kg, 7.5mg for body weight 50 to 100kg, 10mg for body weight greater than 100kg. i) Treatment of acute Deep Treatment should be657 Fondaparinux Sodium 12.5 B01AX05520P5002X A* Vein Thrombosis (DVT). continued for at least 5 days mg/ml Injection in Prefilled X ii) Treatment of Pulmonary and until adequate oral Syringe Embolism (PE) anticoagulation is established (INR 2 to 3). Concomitant treatment with vitamin K antagonists should be initiated as soon as possible, usually within 72 hours. The usual duration of treatment is 5 to 9 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 119 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 2.5 mg once daily given by SC, administered 6 hr following surgical closure provided homeostasis has been established. Usual duration of therapy is 5 to 9 days; for hip fracture patients, an extended course of up to 24 days is recommended. ii) ADULT more than 18 years: 2.5 mg once daily given by SC, initiated as soon as possible after i) Prevention of venous diagnosis and continued for thromboembolic events up to 8 days or until hospital (VTE) in orthopedic surgery discharge. If patient needs to (e.g. hip fracture, major knee undergo PCI, unfractionated or hip replacement surgery), heparin to be admin as per abdominal surgery in patients local practice protocol, taking at risk of thromboembolic into account the patient's complication. bleeding risk and time of last ii) Treatment of unstable dose of fondaparinux.658 Fondaparinux Sodium 2.5 B01AX05520P5001X A* angina or non-ST segment Fondaparinux may be mg/0.5 ml Injection X elevation myocardial restarted no earlier than 2 hr infarction [UA/NSTEMI] in after sheath removal. patients for whom urgent iii) ADULT more than 18 invasive management (PCI) years: 2.5 mg once daily; first is not indicated. dose to be given IV (directly iii) Treatment of ST segment through an existing IV line or elevation myocardial as infusion in 25 or 50 ml of infarction (STEMI) in patients 0.9% saline over 1-2 min), managed with thrombolytics subsequent doses to be or are not receiving other given SC. Treatment to be forms of reperfusion therapy initiated as soon as diagnosis is made and continued up to a max of 8 days or until hospital discharge, whichever comes earlier. If patient needs to undergo non- primary PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 3 hr after sheath removal Framycetin Sulphate 0.5%, S01CA01991D1001 Apply 2 - 3 drops 3 to 4 times Dexamethasone 0.05% and XX daily659 Gramicidin 0.005% Ear A/KK Otitis externa Drops Initially 20 -40 mg IM or slow660 Frusemide 10 mg/ml C03CA01000P3001 B Pulmonary oedema IV (rate not exceeding 4 Injection XX mg/min). CHILD: 0.5 - 1.5 mg/kg. Max: 20 mg dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 120 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: Initial 40 - 80 mg on661 Frusemide 40 mg Tablet C03CA01000T1001X B Pulmonary oedema morning if required, can be X increased to a max of 1 g/day in certain cases especially in chronic renal failure. CHILD : 1 - 3 mg/kg daily Adult: 100-150g every 2-4 Adsorbent in pesticide hours. Child: 1-2g/kg. (100g V03AB00000F2101X poisoning of Fuller's Earth is mixed with662 Fuller's Earth Powder X C 200ml water. Repeat until Fuller's Earth is seen in stool (normally between 4-6 hours) ADULT: 1 oral or 1 nasal Local antibiotic, anti- inhalation 4 hourly, withdraw inflammatory treatment of if no improvement after 7663 Fusafungine 1% Nasal R02AB03000A4101X A infectious and inflammatory days. CHILD : 1 oral or 1 Spray X syndromes of the respiratory nasal inhalation 6 hourly, mucosa withdraw if no improvement after 7 days Treatment of infections664 Fusidate, Sodium 250 mg J01XC01520T1001X A* caused by susceptible ADULT: 500 mg 3 times Tablet X organisms especially daily, skin and soft tissue Staphylococcal infections infection: 250 - 500 mg twice including Methicillin Resistant daily Staphylococcus aureus (MRSA) 1 drop in conjunctival sac 12 hourly. To be continued for 2 days after the eye appears665 Fusidic Acid 1% Eye Drops S01AA13000D2001X A For staphylococcal infections normal. On the first day of X treatment, may be applied more frequently: 1 drop 4 hourly. Surgical prophylaxis : 1 drop every 12 hours, 24 - 48 hours before operation Skin infections caused by staphylococci, streptococci,666 Fusidic Acid 2% Cream D06AX01000G1001 A corynebacterium Apply to affected area 2 - 3 XX minutissumun and other times daily sodium fusidate-sensitive organisms Inflammatory dermatosis where bacterial infection is likely to occur eg atopic Uncovered lesion- Apply 2 to Fusidic Acid 2% in eczema, discoid eczema, 3 times daily. Covered667 Betamethasone Valerate D07CC01948G1001 XX A/KK stasis eczema, seborrhoic lesions- Less frequent 0.1% Cream dermatitis, contact dermatitis, applications may be lichen simplex chronicus, adequate psoriasis, discoid lupus erythematosus668 Fusidic Acid 50 mg/ml J01XC01000L8001X A* Treatment of infections ADULT: 15 ml 3 times daily. Suspension X caused by staphylococcal CHILD 1 - 5 years: 5 ml 3 especially Methicillin times daily; 5 - 12 years: 10 Resistant Staphylococcus ml 3 times daily. INFANT : 1 aureus (MRSA) ml/kg body weight daily in 3 - 4 divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 121 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: 500 mg 3 times daily Treatment of severe diluted to 250 - 500 ml infused slowly over 2 hours. staphylococcal infections Maximum: 2 g daily. CHILD Fusidic Acid 500 mg J01XC01520P4001X especially Methicillin and INFANT : 20 mg/kg/day669 Injection X A* Resistant Staphylococcus divided into 3 equal doses infused slowly over 2 - 4 aureus (MRSA). To be used hours in combination therapy only ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administering 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1,670 Gabapentin 100 mg Tablet N03AX12000T1002X A* i) Add-on therapy for 300mg BD on day 2, 300mg X intractable partial epilepsy, TDS on day 3. Thereafter, refractory to standard anti- then dose may be increased epileptic drugs ii) Treatment in 3 equally divided doses up of various types of to max 3600mg/day.CHILD neuropathic pain, both 3-12 yr: Initially 10-15 peripheral (which includes mg/kg/day in 3 divided dose. diabetic neuropathy, post- Effective dose: CHILD 3 to herpetic neuralgia, trigeminal less than 5 yrs: 40mg/kg/day neuralgia) in adult more than in 3 divided doses, CHILD 5- 18 years 12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1,671 Gabapentin 300 mg N03AX12000C1001 A* i) Add-on therapy for 300mg BD on day 2, 300mg Capsule XX intractable partial epilepsy, TDS on day 3. Thereafter, refractory to standard anti- may be increased in 3 epileptic drugs equally divided doses up to ii) Treatment of various types max 3600mg/day.CHILD 3- of neuropathic pain, both 12 yr: Initially 10-15 peripheral (which includes mg/kg/day in 3 divided dose. diabetic neuropathy, post- Effective dose: CHILD 3 to herpetic neuralgia, trigeminal less than 5 yrs: 40mg/kg/day neuralgia) in adult more than in 3 divided doses, CHILD 5- 18 years 12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 122 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose672 Gabapentin 600 mg Tablet N03AX12000T1001X A* i) Add-on therapy for as: 300mg once on day 1, X intractable partial epilepsy, 300mg BD on day 2, 300mg refractory to standard anti- TDS on day 3. Thereafter, epileptic drugs may be increased in 3 ii) Treatment of various types equally divided doses up to of neuropathic pain, both max 3600mg/day.CHILD 3- peripheral (which includes 12 yr: Initially 10-15 diabetic neuropathy, post- mg/kg/day in 3 divided dose. herpetic neuralgia, trigeminal neuralgia) in adult over 18 Effective dose: CHILD 3 to years less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5- 12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day i) MRI of the liver for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. Hepatocellular carcinoma) or metastatic673 Gadobenate Dimeglumine V08CA08996P3001X A* disease; i) MRI of liver: 0.05ml/kg Injection Solution X ii) MRI of the brain and spine body weight. This where it improves the corresponds to 0.1ml/kg of detection of lesion and the 0.5M solution provides diagnostic ii) MRI of brain & spine: information additional to that 0.1mmol/kg body weight. obtained with unenhanced This corresponds to 0.2ml/kg MRI; of the 0.5M solution iii) Contrast-enhanced MR- iii) MRA: 0.1mmol/kg body angiography where it weight. This corresponds to improves the diagnostic 0.2ml/kg of the 0.5M solution accuracy for detecting clinically significant steno- occlusive vascular disease in patients with suspected or known vascular disease of the abdominal or peripheral arteries. In adults, adolescents and children aged 2 years and older with diagnostic difficulty especially in patients with A single intravenous injection674 Gadobutrol 1 mmol/ml V08CA09000P3001X A* renal impairment for: of 0.1 mmol/kg (equivalent to injection X i) Contrast enhancement in 0.1 ml/kg body weight). Max: cranial and spinal magnetic 0.3 mmol/kg (equivalent to resonance imaging (MRI). 0.3 ml/kg body weight) ii) Contrast enhanced MRI of liver or kidneys in patients with high suspicion orUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 123 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY evidence of having focal675 Gadopentetate V08CA01000P3001X lesion to classify these The usual dose in adults, Dimeglumine 469 mg/ml X A lesions as benign or children, and neonates is 0.2 malignant. mL/kg (0.1 mmol/kg) Gadoterate Meglumine V08CA02254P3001X A iii) Contrast enhancement in intravenously. For cranial and676 (Gadoteric Acid) 0.5 mmol/ X A* Magnetic Resonance spinal imaging, a further dose C Angiography (CE-MRA). of 0.2 mL/kg (0.1 mmol/kg) ml Injection V08CA10520P3001X C may be given within 30 X i) Cranial and spinal minutes if necessary; in Gadoxetic acid disodium magnetic resonance imaging adults this second dose may 0.25 mmol/ml solution for P03AB02100L6001X ii) Whole body magnetic be 0.4 mL/kg (0.2 mmol/kg).677 injection (10ml pre-filled X resonance imaging For whole body imaging in adults and children over 2 syringe) P03AB02100L9901X High risk patients undergoing years, a dose of 0.4 mL/kg X Magnetic Resonance (0.2 mmol/kg) may be678 Gamma Benzene Imaging for cerebral and needed in some cases to Hexachloride 0.1 % Lotion spinal disease, diseases of produce adequate contrast the vertebral column and and in special circumstances Gamma Benzene other whole body pathology a dose of 0.6 mL/kg (0.3679 Hexachloride 0.1% in Oil mmol/kg) may be used in For use in adults for the adults Solution enhancement of magnetic The recommended dose is resonance imaging (MRI) of 0.1 mmol/kg (equivalent to focal liver lesions 0.2 mL/kg in adults, children Scabies and infants. In angiography, depending on the results of Head lice the examination being performed, a second injection may be administered during the same session if necessary 0.1ml/kg body weight (equivalent to 25 µmol per kg body weight). Not recommended for patients younger than 18 years Apply lotion to entire body from neck down for 8 to 12 hours, then rinse Apply a sufficient quantity of shampoo onto clean, dry hair; generally 1 ounce is sufficient, no more than 2 ounces should be used. Work the shampoo into hair thoroughly and allow to remain on hair for 4 minutes. Add small quantities of water and massage until a good lather forms. RinseUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 124 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY680 Gamma Benzene P03AB02100G1002 Only for scabies in adult thoroughly and towel dry Hexachloride 1% Cream XX A/KK briskly A* Treatment of Scabies Adult: Apply a thin681 Ganciclovir Sodium 50 mg/ J05AB06520P3001X A* cytomegalovirus (CMV) layer of 1% topical ml Injection X A* disease in preparation onto all skin immunocompromised areas from the neck to toes.682 Ganirelix 0.25 mg/0.5 ml H01CC01000P2001 A* patients, prevention of CMV Completely wash off from the Injection XX disease during body with warm water after 8- immunosuppressive therapy 12 hr.683 Gefitinib 250 mg tablet L01XE02000T1001X following organ Initial: 5 mg/kg infused over 1 X transplantation hour 12 hourly for 14 - 21684 Gemcitabine HCl 1 g Prevention of premature days (CMV retinitis Injection L01BC05110P4002X luteinizing hormone surges in treatment) or 7 - 14 days X women undergoing controlled (CMV disease prevention). ovarian hyperstimulation for Long term maintenance: 6 assisted reproduction mg/kg daily for 5 days/week technique or 5 mg/kg daily for 7 For the treatment of patients days/week with locally advanced or metastatic non-small cell lung Given by SC 0.25 mg once cancer (NSCLC) who have daily, starting on day 6 of previously failed ovarian stimulation and chemotherapy, and who have continued until ovulation activating mutation of induction epidermal growth factor receptor (EGFR). Restricted 250mg tablet once a day, to non-smoker, female, taken with or without food EGFR positive and Asian patients only. i) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every i) Locally advanced or 3 weeks or 1000 mg/m2 day metastatic non-small cell lung 1, day 8, day 15 every 4 cancer weeks ii) Locally advanced or ii) Initially 1000 mg/m2 metastatic pancreatic cancer weekly for 7 weeks followed iii) In combination with by 1 week rest. Subsequent carboplatin in the treatment cycles 1000 mg/ m2 weekly of patients with recurrent for 3 weeks followed by 1 epithelial ovarian carcinoma, week rest who have relapsed more iii) Gemcitabine 1000 mg/m2 than six months, following as 30 minutes IV infusion day platinum-based therapy 1 & 8 of each 21-day cycle iv) In combination with followed by carboplatin on paclitaxel for treatment of day 1 to attain a target AUC patients with metastatic of 4 mg/ml/minute breast cancer who have iv) 1250 mg/m2 on days 1 relapsed following adjuvant/ and 8 of each 21-day cycle neoadjuvant chemotherapy. with paclitaxel 175 mg/m2 Prior chemotherapy should given as a 3-hour infusion have included anUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 125 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY anthracycline unless clinically before gemcitabine on day 1 contraindicated of each 21-day cycle685 Gemcitabine HCl 200 mg L01BC05110P4001X A* i) Locally advanced or i) Alone or with cisplatin: Injection X metastatic non-small cell lung 1000 mg/m2 day 1 & 8 every cancer 3 weeks or 1000 mg/m2 day ii) Locally advanced or 1, day 8, day 15 every 4 metastatic pancreatic cancer weeks ii) Initially 1000 mg/m2 iii) In combination with weekly for 7 weeks followed carboplatin in the treatment by 1 week rest. Subsequent of patients with recurrent cycles 1000 mg/ m2 weekly epithelial ovarian carcinoma, for 3 weeks followed by 1 who have relapsed more week rest than six months, following iii) Gemcitabine 1000 mg/m2 platinum-based therapy as 30 minutes IV infusion day iv) In combination with 1 & 8 of each 21-day cycle Paclitaxel, for treatment of followed by carboplatin on patients with metastatic day 1 to attain a target AUC breast cancer who have of 4 mg/ml/minute relapsed following adjuvant/ iv) 1250 mg/m2 on days 1 neoadjuvant chemotherapy. and 8 of each 21-day cycle, Prior chemotherapy should with paclitaxel 175 mg/m2 have included an anthracycline unless clinically given as a 3-hour infusion contraindicated before gemcitabine on day 1 of each 21-day cycle Gemeprost (Prostagladin G02AD03000S1001 A Inducing abortion in the first Cervical dilatation: 1 pessary686 E1 Synthetic Analogue) 1 XX trimester 3 hourly before surgery to a max of 5 pessaries over 24 mg Pessary hours ADULT: 1200 mg/day in 2 Gemfibrozil 300 mg C10AB04000C1001 Treatment of divided doses, 30 minutes687 Capsule XX A/KK hyperlipoprotinaemias before breakfast and dinner. (TYPES IIA, IIB, III, IV, V) Dose range from 0.9-1.5 g daily688 Gentamicin 0.1% Cream D06AX07183G1001 A* For localised infections Apply 2 - 3 times daily XX Broad spectrum antibiotic in 1 - 2 drops every 4 hours, in689 Gentamicin 0.3% Eye S01AA11183D2001X A/KK superficial eye infections and severe infection dosage may Drops X also for Pseudomonas be increased up to 2 drops aeruginosa every hour Conjunctivitis, blepharitis, blepharo-conjunctivitis,690 Gentamicin 0.3% Eye S01AA11183G5101 A/KK keratitis, keratoconjunctivitis, Apply into the conjunctival Ointment XX episcleritis, dacrocystitis, sac 3 - 4 times daily corneal ulcers, styes and infected eye socket Broad spectrum antibiotic in691 Gentamicin 3% Fortified S01AA11183D2002X A superficial eye infections and Dose according to the needs Eye Drops X also for Pseudomonas of the patient aeruginosaUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 126 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE692 Gentamicin 7.5 mg Beads J01GB03183P1001X CATEGORY Treatment of chronic osteomyelitis of post- 7.5 - 22.5 mg chains to fill693 Gentamicin Sulphate 10 X A traumatic, post-operative or affected cavity mg/ml Injection J01GB03183P3002X B hematogenous origin B ADULT: 3 - 5 mg/kg/day 8694 Gentamicin Sulphate 40 X Infections due to susceptible hourly IM or IV. CHILD up to mg/ml Injection J01GB03183P3003X A/KK organisms 2 weeks: 3mg/kg every 12 hours; 2 weeks - 12 years: 2 Gentamicin Sulphate and X A Infections due to susceptible mg/kg 8 hourly695 Betamethasone Disodium organisms ADULT: 3 - 5 mg/kg/day 8 S01CA05990D2001 B hourly IM or IV. CHILD up to Phosphate Eye Drops XX B Inflammatory and allergic 2 weeks: 3mg/kg every 12 conditions involving hours; 2 weeks - 12 years: 2 Gentamicin Sulphate and S01CA05990G5101 B superficial eye structures and mg/kg 8 hourly696 Betamethasone Disodium XX when bacterial infection is present : conjunctivitis, 2 drops 3 - 4 times daily Phosphate Eye Ointment A10BB01000T1001X blepharitis, keratitis, X episcleritis, dacryocystitis, Thin coating of ointment 3 - 4697 Glibenclamide 5 mg Tablet hordeolum, meibomianitis, times daily A10BB09000T5002X injuries involving anterior698 Gliclazide 30 mg Modified X segment of the eye Range: 2.5 - 15 mg daily Release Tablet Inflammatory and allergic (with or immediately after A10BB09000T5001X conditions involving breakfast). Initially 2.5 mg699 Gliclazide 60 mg Modified X superficial eye structures and daily increasing by 2.5 mg Release Tablet when bacterial infection is required for metabolic present : conjunctivitis, control. Max: 20mg daily. blepharitis, keratitis, Initially, 30mg daily at episcleritis, dacryocystitis, breakfast time, may increase hordeolum, meibomianitis, in successive steps to 60, 90 injuries involving anterior or 120mg daily at 1 month segment of the eye intervals. Max daily dose: 120mg Diabetes mellitus type 2. Initially, 30mg daily at Restriction : Use only in breakfast time, may increase patient under 65 years old in successive steps to 60, 90 or 120mg daily at 1 month Diabetes mellitus type 2 intervals (except in patients whose blood glucose level Diabetes mellitus type 2 was not reduced after 2 weeks of treatment). Max daily dose: 120mgUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 127 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Initially 40-80mg daily. A700 Gliclazide 80 mg Tablet A10BB09000T1001X B Diabetes mellitus type 2 single dose should not X exceed 160mg and when higher doses are required, a701 Glucagon (Lyophilised) 1 H04AA01000P4001X B Management of twice daily split dosage is mg/ml Injection X hypoglycaemia advised and should be divided. Maximum daily dose: 320mg. For elderly, starting dose should be 40mg twice daily. Adult, children > 20kg: 1mg by SC, IM or IV. Children < 20kg: 0.5mg. If patient does not respond within 10 minutes, administer IV glucose. Repeat in 20 minutes if necessary.702 Glutaraldehyde Solution 2% V07AV00000L9905X A 2% formulation - High level 20 minutes or more X disinfection for heat sensitive immersion is recommended equipments such as for endoscopes before the703 Glycerin A06AX01000L5001X C+ endoscopes session and between X C+ patients after thorough As a lubricant and osmotic cleaning based on A06AG20921G2001 C dehydrating agent manufacturer XX recommendation Apply to area when required704 Glycerin 25% and Sodium Constipation 1 enema as required Chloride 15% Enema705 Glyceryl Trinitrate 0.5 mg C01DA02221T1001X Prophylaxis and treatment of 0.5-1 mg sublingually may be Sublingual Tablet X angina and left ventricular repeated every 5 minutes failure until relief is obtained. Seek706 Glyceryl Trinitrate 5 mg/ml C01DA02221P3001 A physician if the pain persists Injection XX Prophylaxis and treatment of after a total of 3 tablets in a angina, left ventricular failure. 15 minutes period. Glyceryl Trinitrate Aerosol C01DA02221A1001 B Not for direct IV injection.707 Spray 400mcg (metered XX Initial 5 mcg/min delivered via Prophylaxis and treatment of infusion pump. Subsequent dose) angina and left ventricular titration must be adjusted to failure clinical situation with dose increment becoming more cautious as partial response is seen. At the onset of an attack, one or two metered sprays should be administered on or under the tongue. A spray maybe repeated approximately every 5 minutes as needed. No more than 3 metered sprays are recommended within 15 minute period. If chest pain persists after a total of 3 sprays, prompt medical attention is recommended. Aerosol may be used prophylactically 5 toUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 128 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 10 minutes before engaging in activities that might precipitate an acute attack708 Glycine 1.5% Irrigating B05CX03000H3001 A Bladder irrigation during The dosage depends on the Solution XX genitourinary surgery extent of the procedure and its duration709 Glycopyrrolate 200 mcg/ml A03AB02320P3001X A* i) To reduce secretions i) Pre-op: 4 mcg/kg via IM Injection X (respiratory tract) for certain administration 30-60 mins types of surgery before procedure. Glycopyrronium 50mcg, R03BB06320A2001X A/KK ii) Reversal of neuromuscular Intraoperative: 0.1 mg via IV710 Inhalation Powder Hard X block in patients where administration, repeat at 2-3 atropine is contraindicated min intervals when needed. Capsules Max: 400 mcg/dose. For maintenance ii) 0.2 mg by IV for each 1 mg Golimumab 50mg (0.5ml) L04AB06000P5001X A* bronchodilator treatment to of neostigmine or 5 mg711 solution for injection in a X relieve symptoms in adult pyridostigmine patients with chronic One capsule daily. The pre-filled syringe obstructive pulmonary recommended dose is the disease (COPD). COPD inhalation of the content of diagnosis is confirmed by one capsule once daily using spirometry. inhaler. It is recommended to be administered, at the same i) Rheumatoid arthritis (RA): time of the day each day. No In combination with relevant use of methotrexate (MTX), is glycopyrronium in pediatric indicated for: - The treatment population (<18 years) for of moderate to severe active COPD. rheumatoid arthritis in adult patients when the response i) Rheumatoid arthritis 50mg to DMARD therapy including given as a subcutaneous MTX has been inadequate. - injection once a month, on The treatment of active, the same date each month. severe and progressive ii) Psoriatic arthritis 50mg rheumatoid arthritis in adult given as a subcutaneous patients not previously injection once a month, on treated with MTX. the same date each month. ii) Psoriatic arthritis (PsA): iii) Ankylosing spondylitis Golimumab alone or in 50mg given as a combination with MTX, is subcutaneous injection once indicated for: The treatment a month, on the same date of active psoriatic arthritis in each month. adult patients when the response to previous DMARD therapy has beenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 129 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY inadequate. iii) Ankylosing spondylitis (AS): Golimumab (used alone) is indicated for: The treatment of active ankylosing spondylitis in adult patients when the response to conventional therapy has been inadequate. Prostate cancer,endometriosis,leiomy One 10.8mg depot injected oma uteri and assissted712 Goserelin 10.8 mg Depot L02AE03000P2002X A reproduction,breast cancer in subcutaneously into the Injection X premenopausal and anterior abdominal wall, perimenopausal women every 12 weeks. suitable for hormonal manipulation Prostate cancer,endometriosis,leiomy oma uteri and assissted713 Goserelin 3.6 mg Depot L02AE03000P2001X A reproduction,breast cancer in 3.6 mg depot injection every Injection X premenopausal and 28 days perimenopausal women suitable for hormonal manipulation ADULT 1 mg twice daily or 2714 Granisetron HCl 1 mg A04AA02110T1001X A Prevention and treatment of mg once daily with the first Tablet X nausea and vomiting dose to be administered associated with within 1 hour prior to chemotherapy and cytostatic therapy and can be radiotherapy given for up to 1 week following radiotherapy. Maximum 9 mg/day i) ADULT 1-3 mg as an IV bolus not not less than 30 i) Prevention and treatment seconds; maximum 9 of nausea and vomiting mg/day. CHILD over 2 years;715 Granisetron HCl 1 mg/ml A04AA02110P3001X A associated with single dose of 10-40 mcg/kg Injection X chemotherapy and as an IV infusion; maximum 3 radiotherapy mg/day ii) Post-operative nausea and ii) ADULT 1 mg by slow IV vomiting injection over 30 seconds prior to induction of anaesthesiaUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 130 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: 500 mg daily up to 1 g daily in divided doses, 2-8716 Griseofulvin (Ultramicrosize D01BA01000T1001X B Dermatophyte infections of wk in hair and skin infections, 125 mg = 250 mg X the skin, scalp, hair and nails, 6 mth in fingernail infections Microsize) Tablet where topical therapy has and 12 mth or more for failed or inappropriate toenail infections. CHILD: 10 mg/kg daily in divided doses or as a single dose For acute renal failure, chronic renal failure,717 Haemodialysis Concentrate B05ZA00908H1001X A overhydration, intoxication, Dose depending on clinical with Acetate X adjustment of acid-base and cases electrolyte balance For acute renal failure,718 Haemodialysis Concentrate B05ZA00908H1002X A chronic renal failure, Dose depending on clinical with Bicarbonate X overhydration, intoxication, cases adjustment of acid-base and electrolyte balance Haemophilus Influenza J07AG01000P4001X C Immunisation of infants 0.5 ml IM719 Type B Conjugate Vaccine X against Haemophilus Influenzae Type B Injection (Single Dose) Adult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases.720 Haloperidol 1.5 mg Tablet N05AD01000T1001X B Schizophrenia and other Usual maintenance: 3-10 mg X psychoses daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day. Adult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases.721 Haloperidol 5 mg Tablet N05AD01000T1002X B Schizophrenia and other Usual maintenance: 3-10 mg X psychoses daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day. ADULT: IM or IV , 2 mg - 10 mg then every 4 - 8 hours722 Haloperidol 5 mg/ml N05AD01000P3001 B Acute psychoses and mania according to response to total Injection XX maximum 18 mg daily. Use in child is not recommendedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 131 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY723 Heparin 1000 units/ml B01AB01520P3001X i) Prophylaxis and treatment i) By IV injection, loading Injection X B of venous thrombosis and dose of 5000 units (10,000 pulmonary embolism. units in severe pulmonary724 Heparin 5000 units/ml B01AB01520P3002X B ii) Treatment of myocardial embolism) followed by Injection X infarction and arterial continuous infusion of 15-25 embolism. units/kg/hr. By SC injection iii) Prevention of clotting in (for DVT) of 15,000 units arterial and heart surgery and every 12 hours (laboratory for prevention of cerebral monitoring on daily basis thrombosis essential to adjust dose). Small adult or child, lower i) Prophylaxis and treatment loading dose then, 15-25 of venous thrombosis and units/kg/hr by IV infusion, or pulmonary embolism. 250 units/kg every 12 hours ii) Treatment of myocardial by SC injection. infarction and arterial ii) As i), for unstable angina embolism. and acute peripheral arterial iii) Prevention of clotting in occlusion. arterial and heart surgery and iii) Prophylaxis in general for prevention of cerebral surgery, by SC injection, thrombosis 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected i) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted doseUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 132 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected725 Heparin Sodium 50 units in B01AB01930P3001X B To maintain patency of Flush with 5 ml (50 units) Sodium Chloride Injection X peripheral venous catheters every 4 hours or as required Vaccination against hepatitis A especially in those at risk 0.5 ml per injection. ADULT of exposure to hepatitis A and CHILD more than 15 virus such as: years: A single primary dose Hepatitis A, Inactivated J07BC02000P5001X A X i) Visitors followed by a booster dose 6726 Vaccine 160 antigen units Injection ii) Chronic hepatitis B and C - 12 months later. CHILD 2 - patient 15 years: A single primary iii) Those requiring dose followed by a booster vaccination against hepatitis dose 6 - 12 months later A i) Adults: Recommended Dose: 1000-2000 IU IM and if necessary, the dose should be increased or repeated. Children: Inject 32-48 IU/kg of body weight, should be administered within 7 days after exposure to HBsAg727 Hepatitis B Immunoglobulin J06BB04000P3001X A i) For post-exposure (preferably within 48 hrs). (Human) Injection X prophylaxis of hepatitis B Neonates: Recommended ii) Prophylaxis against Initial Dose: 100-200 IU. The recurrence of hepatitis B 1st dose should be infection in chronic hepatitis administered within 5 days B post liver transplantation after birth (preferably within 48 hrs) and booster dose should be 32-48 IU/kg body weight. The booster dose should be administered between 2 and 3 months after the 1st administration. ii) Different regimens depending on hepatitis B virus (HBV) DNA positivity ADULTS over 20 years: 10 mcg/dose. ADOLESCENT 11 - 19 years: 5 mcg/dose. NEWBORN and CHILD up to728 Hepatitis B Vaccine J07BC01000P4001X C+ Immunisation against 10 years: 2.5 mcg/dose. Injection X infections caused by INFANTS born to HBsAg Hepatitis B virus positive mothers: 3 doses of 0.5 ml each. Second dose to be given after 1 month and booster dose after 6 monthsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 133 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Adult: Instill 1 or 2 drops of 2% solution immediately before the procedure, repeat at 5-10-minute intervals if necessary. Child: Instill 1 drop of 2% soln immediately i) Mydriasis and cycloplegia before the procedure, repeat729 Homatropine 2% Eye Drops S01FA05330D2003X B for refraction at 10-min intervals if X ii) Treatment of anterior necessary. segment inflammation ii) Adult: Instill 1-2 drops of 2% bd-tds up to every 3-4 hr as needed. Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bd. i) ADULT 25 g. CHILD 0.6 g/kg body weight730 Human Albumin Injection B05AA01000P3001X B i) Acute hypovolemic shock ii) Maximum daily dose is 2g X ii) Hypoproteinaemia iii) 1 g/kg before exchange iii) Neonatal transfusion. Dose is given at hyperbilirubinaemia rate of 1 ml of 25% solution per minute i) Hypogammaglobulinaemia i) 50 mg/kg body weight daily and other deficiency states for 5 days, then 25 - 50 ii) Severe refractory mg/kg weekly for idiopathic thrombocytopenia maintenance according to the purpura (platelet less than severity of the condition 20,000) with internal ii) 400 mg/kg daily for 5 days731 Human Normal Globulin J06BA02000P3001X A bleeding, particularly central with a further dose of 400 Injection X nervous system mg/kg as required iii) Septicaemia in iii) Septicaemia in immunocompromised immunocompromised patients or patients not patients or patients not responding to antibiotics responding to antibiotics iv) Chronic lymphocytic iv) 250 mg/kg per month leukaemia not responding to Dose varies depending on conventional therapy brand used Human Papillomavirus J07BM02000P3001X C+ For the prevention of cervical Given by IM into deltoid732 (Types 16, 18) Vaccine X cancer due to papilloma region. ADULT and CHILD virus. To be used as part of 10 - 25 years, 3 doses of 0.5 Injection the public health program mL, at 0, 1 and 6 months only For the prevention of cervical Given by IM into deltoid Human Papillomavirus J07BM01000P3001X C+ cancer due to papilloma region or higher anterolateral733 (Types 6, 11, 16, 18) X virus. To be used as part of thigh. ADULT and CHILD 9 - the public health program 26 years, 3 doses of 0.5 mL, Vaccine Injection only at 0, 2 and 6 months i) Slow IV injection, ADULT: 5-10 mg diluted with 10ml sodium chloride 0.9%. May734 Hydralazine HCl 20 mg C02DB02110P3001 B Hypertensive crisis in be repeated after 20-30 Injection XX pregnancy minutes if necessary. ii) IV infusion 200-300 mcg/minutes. Maintenance dose 50-150 mcg/minutesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 134 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX735 Hydrochlorothiazide 25 mg C03AA03000T1001X B Diuretic, hypertension dose, not to exceed 100 mg Tablet X ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses;736 Hydrochlorothiazide 50 mg C03AA03000T1002X B Diuretic, hypertension Children 2-12 years old MAX Tablet X dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily Inflammatory and pruritic Apply to affected part 2-3737 Hydrocortisone 1% & D07CA01952G1001 B manifestations of times daily (occasionally may Neomycin 0.5% Cream XX corticosteroid responsive cause sensitisation to dermatoses Neomycin) Inflammatory and pruritic Apply sparingly to affected738 Hydrocortisone 1% Cream D07AA02000G1001 B manifestations of area 2 - 3 times daily until XX corticosteroid responsive condition improve, then dermatoses reduce frequency Hydrocortisone 1% Inflammatory and pruritic Apply sparingly to affected Ointment D07AA02000G5001 manifestations of area 2 - 3 times daily until739 XX B corticosteroid responsive condition improve, then dermatoses reduce frequency Glucocorticoid replacement therapy in primary or740 Hydrocortisone 10 mg H02AB09000T1001X B secondary adrenal ADULT: 20 - 30 mg daily in Tablet X insufficiencies and long term divided doses. CHILD: 10 - management of congenital 30 mg daily in divided doses adrenal hyperplasia in children ADULT 100 mg 1-2741 Hydrocortisone Enema A07EA02000G2001 B Adjunctive treatment for times/day for 2-3 weeks. If 0.1% XX ulcerative colitis and proctitis used for longer than 3 weeks, taper treatment over 2-3 weeks742 Hydrocortisone Sodium H02AB09520P4001X C Conditions responsive to Initially 100 - 500 mg IV over Succinate 100 mg Injection X systemic or local 30 seconds to more than 10 glucocorticoid injection minutes. Dose may beUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 135 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY repeated at intervals of 2, 4 therapy especially in or 6 hours emergencies Instill 1 - 2 drops into the ear743 Hydrogen Peroxide 1.5% S02AA06241D1001X C To soften impacted ear wax as required (leave for a few Ear Drops X minutess) Hydrogen Peroxide 6%744 Hydrogen Peroxide 20 D08AX01241L9901X C Skin disinfection, particularly (=approx. 20 vol) shall be volume Solution X cleansing and deodorising dispensed. For cleansing wounds and ulcers wounds: 1.5% to 6% solution apply 2-3 times daily or when i) SLE and mixed connective nescessary. As a mouthwash: rinse the mouth745 Hydroxychloroquine P01BA02183T1001X A tissue disease for skin, joint for 2-3 minutes with 15ml of Sulphate 200 mg Tablet X and serosa hydrogen peroxide 6% ii) Second line therapy for diluted in half a tumblerful of acute rheumatoid arthritis warm water 2-3 times daily. Disinfecting cleaned746 Hydroxyethyl Cellulose Jelly V07AY00250G4001 B For lubricating purpose equipment: immersion for 30 XX minutes in 6% solution. As ear drop for removal of wax: Therapy and prophylaxis of hydrogen peroxide 6% diluted with 3 parts of water747 Hydroxyethyl Starch 6% B05AA07000P9901X B hypovolaemia and shock in preferably just before use Injection X connection with surgery i) Initially 400 mg daily in divided dose. Maintenance: trauma, infections and burns 200 - 400 mg daily ii) ADULT: 400 - 600 mg Hydroxyprogesterone G03DA03128P2001 A Habitual and threatened daily. Maintenance: 200 - 400748 Caproate 250 mg/ml XX abortion mg daily. CHILD : up to 6.5 mg/kg daily (maximum Injection 400mg daily) Apply sufficiently for i) Solid tumours lubricating purpose ADULT daily dose up to 20 ii) Chronic myelocytic ml/kg/day. Normally 500- 1500 ml. The rate of infusion leukaemia and may approach 20 ml/kg/hour myeloproliferative disease in acute haemorrhagic shock,749 Hydroxyurea 500 mg L01XX05000C1001X A iii) Severe psoriasis eg. slower rates in burns and Capsule X Extensive plaque psoriasis, septic shock. CHILD under 10 years do not exceed 15 ml erythrodermic psoriasis, /kg/hour. pustular psoriasis -as third 250 - 500 mg once weekly by line therapy. IM injectionUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd day. Continuous therapy: 20 - 30 mg/kg orally as a single dose dly. Concomitant therapy with irradiation: 80 mg/kg orally as a single dose every 3rd day (administration of hydroxyurea should be started at least 7 days before initiation of irradiation and 136 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY continued during radiotherapy as well). ii) Continuous therapy (20 - 30 mg/kg orally as a single dose daily, therapy should be interrupted if the white blood cell count drops below 2500/mm3, or the platelet count below 100,000/mm3. iii) 500 mg tds. Initially 25 mg at night, increased if necessary up to Hydroxyzine HCl 25 mg N05BB01110T1001X 25 mg 3-4 times daily. Tablet X ADULT and CHILD more750 A Allergic pruritus than 10 years : 50 - 75 mg; 6 - 10 years: 25 - 50 mg; 2 - 5 years: 12.5 - 25 mg; to be taken daily in divided doses 200-600 mcg given as SC or Hyoscine Hydrobromide A04AD01330P3001X To reduce oral secretions IM 60 minutes before751 400 mcg/ml Injection X B before surgery induction of anaesthesia. CHILD: 15 mcg/kg752 Hyoscine N-Butylbromide 1 A03BB01320L5001X B Gastrointestinal tract and ADULT 40mg 4 times a day. mg/ml Liquid X genito-urinary tract spasm, CHILD 6-12 years old: 10mg dyskinesia of the biliary 3 times a day. system753 Hyoscine N-Butylbromide A03BB01320T1001X B Gastrointestinal tract and ADULT 40mg 4 times a day. 10 mg Tablet X genito-urinary tract spasm, CHILD 6-12 years old: 10mg dyskinesia of the biliary 3 times a day. system754 Hyoscine N-Butylbromide A03BB01320P3001X B Gastrointestinal tract and 20 mg IM/IV repeated after 20 mg/ml Injection X genito-urinary tract spasm, 30 min if needed. Max: 100 dyskinesia of the biliary mg daily. system755 Hypromellose 0.3% Eye S01XA20000D2002X B Tear deficiency, ophthalmic 1 - 2 drops several times a Drops X lubricant; for relief of dry eyes day and eye irritation Symptomatic relief of severe Hypromellose 0.3%, S01KA02000G3201 B dry eye conditions and as Instill 1-2 drops in affected756 Carbomer 980 Ophthalmic XX lens lubricant during eye(s) as needed ophthalmic diagnostic Gel procedures Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if Ibandronic Acid 150 mg there is positive response, Tablet M05BA06000T1003 treatment may be continued757 XX A* up to 5 years and then re- 150 mg once monthly evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years andUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 137 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY then continue treatment shall758 Ibuprofen 200 mg Tablet M01AE01000T1001 the benefit outweigh the risk. Dosage: ADULT: 200 - 400 XX B mg 3 times daily after food,759 Ichthammol Glycerin 10% C Pain and inflammation in maximum 3.2 g daily. CHILD: Ear Drops S02AA30000D1001X A* rheumatic disease 30-50 mg/kg body weight X daily in divided doses,760 Idarubicin 10 mg Injection A* Ear wick for otitis externa maximum 2.4g daily. Lowest L01DB06110P4002X A* with oedema effective dose for the shortest761 Idarubicin 5 mg Injection X A* possible duration. i) Acute promyelocytic 2 - 3 drops 3 - 4 times daily762 Idursulfase 2 mg/ml L01DB06110P4001X A* leukaemia and in ear wick for otitis Injection X ii) Relapse Acute myeloid externa leukemia (with sibling match) i) Induction phase: 12 mg/m2763 Ifosfamide 1 g Injection A16AB09000P3001X iii) Acute myeloid leukemia, IV slow bolus on Days 3, 5 X acute lymphoblastic leukemia and 7. Consolidation phase,764 Imatinib Mesylate 100 mg (salvage therapy) month 1: 12 mg/m2 IV on Tablet L01AA06000P4001X Days 1 and 2. Repeat X i) Acute promyelocytic monthly for 3 courses leukaemia ii) 12 mg/m2 D1-3 L01XE01196T1001X ii) Relapse Acute myeloid iii) 12 mg/m2 D1-3 as part of X leukemia (with sibling match) FLAG-IDA regimen. Children: iii) Acute myeloid leukemia, 10mg/m2 IV daily for 3 days acute lymphoblastic leukemia i) Induction phase: 12 mg/m2 (salvage therapy) IV slow bolus on Days 3, 5 and 7. Consolidation phase, Hunter syndrome month 1: 12 mg/m2 IV on (Mucopolysaccharidosis II, Days 1 and 2. Repeat MPS ii). monthly for 3 courses ii) 12 mg/m2 D1-3 i) Solid tumours iii) 12 mg/m2 D1-3 as part of ii) Leukaemia FLAG-IDA regimen. Children: iii) Lymphoma 10mg/m2 IV daily for 3 days 0.5 mg/kg of body weight i) ADULT and CHILD: administered every week as Philadelphia positive (Ph+) an intravenous infusion. chronic myeloid leukaemia in i) 1.2 - 2.4 g/m2/day for 3 - 7 chronic phase and in early days as a 30 - 120 minutes acceleration after failure of infusion. Alternatively, can interferon therapy also be given as a single high ii) Treatment of patients with dose, eg. 5 g/m2 in a 24 hour unresectable and/or infusion. Cycles may be metastatic malignant repeated every 3 - 4 weeks gastrointestinal stromal ii) CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol iii) Refer to protocols i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 138 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY tumours (GIST) who are mg/day positive for CD117/c-kit ii) ADULT : 400mg/day765 Imatinib Mesylate 400 mg L01XE01196T1002X A* i) ADULT and CHILD: i) ADULT: Chronic phase Tablet X Philadelphia positive (Ph+) chronic myeloid leukemia: chronic myeloid leukaemia in 400 mg once daily.766 Imiglucerase 400 IU A16AB02000P4002X A* chronic phase and in early Accelerated phase or blast Injection X acceleration after failure of crisis chronic myeloid interferon therapy leukemia: 600 mg once daily.767 Imipenem 500 mg and J01DH51961P4002X A* ii) Treatment of patients with CHILD more than 2 years, Cilastatin 500 mg Injection X unresectable and/or chronic and advanced phase metastatic malignant chronic myeloid leukemia: gastrointestinal stromal 340 mg/m2 daily. Max: 800 tumours (GIST) who are mg/day positive for CD117/c-kit ii) ADULT : 400mg/day Non-neuronopathic (Type 1) or chronic neuronopathic Dosage should be (Type 3) Gaucher disease individualized to each patient. and who exhibit clinically Initial dosages range from significant non-neurological 2.5 units/kg of body weight 3 manifestations of the times a week to 60 units/kg disease. The non- once every 2 weeks. neurological manifestations Administered by intravenous of Gaucher disease include infusion over 1-2 hours. one or more of the following conditions: - anemia, after Based on type or severity of exclusion of other causes, infection, susceptibility of such as iron deficiency - pathogen(s) and patient thrombocytopenia - bone condition including body disease, after exclusion of weight and renal function. other causes, such as ADULT: 1 - 2 g/day in 3 - 4 Vitamin D deficiency - divided doses. Maximum: 4 hepatomegaly or g/day or 50 mg/kg/day. splenomegaly Infusion rate: less than 500 mg dose: over 20 - 30 Severe infections caused by minutes, more than 500 mg: susceptible pathogens dose over 40 - 60 minutes. especially useful in infections CHILDREN: ≥ 40kg body involving ESBL organisms. weight should receive adult Not to be used for doses. CHILDREN AND prophylaxis INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 139 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY The total daily dose should not exceed 2g. Initially up to 75 mg daily in divided doses increased gradually to 150 - 200 mg (up to 300 mg in hospital768 Imipramine HCI 25 mg N06AA02110T1001X B Depression patients); up to 150 mg may Tablet X be given as a single dose at bedtime. ELDERLY initially 10 mg daily; increased gradually to 30 - 50 mg daily; CHILD is not recommended Treatment of external genital Apply to affected area at769 Imiquimod 5 % w/w Cream D06BB10000G1001 A* and perianal warts or bedtime for 3 times a week XX condyloma acuminata in for up to 16 weeks; leave on adults skin for 6-10 hours Immunoglobulin Tetanus J06BB02000P3001X B Passive immunization Prophylaxis of tetanus: IM770 Human 250 Units/Vial X against tetanus 250 units. Treatment of tetanus: IM 30 - 300 units/kg Injection Maintenance bronchodilator Once-daily inhalation of the treatment of airflow content of one 150/300 Indacaterol Maleate 150 R03AC18253C9901771 mcg Inhalation Capsule XX A* obstruction in adult patients microgram capsule. with chronic obstructive Maximum dose is 300 pulmonary disease (COPD). microgram once-daily. Maintenance bronchodilator Once-daily inhalation of the772 Indacaterol Maleate 300 R03AC18253C9902 treatment of airflow content of one 150/300 mcg Inhalation Capsule XX A* obstruction in adult patients microgram capsule. with chronic obstructive Maximum dose is 300 pulmonary disease (COPD). microgram once-daily.773 Indinavir Sulfate 400 mg J05AE02183C1001X A* i) Post-exposure prophylaxis ADULT: 800 mg every 8 Capsule X (PEP) among healthcare hours. CHILD workers in high-risk HIV (investigational): 500 mg/m2 occupational exposure every 8 hours (patients with ii) For therapy as part of smaller body surface area combination antiretroviral (BSA) may require lower treatment on adult HIV doses of 300 - 400 mg/m2 patients ie Highly Active Anti- every 8 hours). Dosage may Retroviral Therapy (HAART) varies depending on types of combination therapy used. Indomethacin 100 mg Pain and inflammation in Adult: As supp: 100 mg to be Suppository M02AA23000S2001 rheumatic arthritis inserted at night and774 XX B repeated in the morning if necessary.775 Indomethacin 25 mg M01AB01000C1001 B Pain and inflammation in 50 - 200 mg daily in divided Capsule XX rheumatic disease doses, with food. Child not recommended.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 140 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Rheumatoid arthritis: ADULT over 18 years old: 3776 Infliximab 100 mg Injection L04AB02000P4001X A* i) Rheumatoid arthritis mg/kg at 0, 2, 6 weeks, then X (moderate to severe), in every 8 weeks; May increase combination with to 10 mg/kg or increase methotrexate dosing frequency to 4 weekly ii) Ankylosing spondylitis in for patients with incomplete patients with active disease response. Discontinue if no despite treatment with response by 12 weeks of methotrexate initial infusion or after dose iii) Crohn's Disease in adjustment patients who have an ii) Ankylosing spondylitis: inadequate response to ADULT over 18 years: 5 conventional therapies. iv) Fistulizing Crohn's mg/kg IV over 2 hour given at Disease in patients who have week 0, 2, and 6 then every an inadequate response to 6-8 weeks. Discontinue if no conventional therapies response by 6 weeks of initial v) Ulcerative Colitis in infusion. patients who have an iii), iv) & v)5 mg/kg given as inadequate response to an intravenous infusion over conventional therapies a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter Influenza Vaccine (Inactivated, trivalent) CHILD 6-35 months: Single Injection (containing 3 Prophylaxis of influenza for dose of 0.5 ml IM or deep777 strains, two type A J07BB02963P3001X B frontliners (KKM staff and SC; 3-8 years: 1-2 doses of subtypes, of which one X must include pandemic A essential services personnel) 0.5 ml IM ADULT & CHILD and in high risk groups more than 9 years: Single (H1N1) and one Type B dose of 0.5 ml IM subtype) Prevention of influenza and influenza related Influenzae Vaccine complications in high risk 19 to 59 years: Single dose (Inactivated,Trivalent) Type adult patients, in particular of 0.1ml 9mcg/strain individuals who have chronic intradermally. ≥ 60 years:778 A (H1N1) 15 mcg, Type A J07BB02963P5002X B cardiovascular, pulmonary, Single dose of 0.1ml (H3N2) 15 mcg & Type B X metabolic or renal disease, or 15mcg/strain intradermally who are 15 mcg Haemagglutinin Injection immunocompromized and elderly patients Prevention of influenza and influenza related Influenzae Vaccine complications in high risk 18 to 59 years: Single dose adult patients, in particular of 0.1ml 9mcg/strain (Inactivated,Trivalent) Type J07BB02963P5001X individuals who have chronic intradermally. ≥ 60 years: A (H1N1) 9 mcg, Type A X cardiovascular, pulmonary, Single dose of 0.1ml779 (H3N2) 9 mcg & Type B 9 B metabolic or renal disease, or 15mcg/strain intradermally who are mcg Haemagglutinin Injection immunocompromized and elderly patientsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 141 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 25% Insulin Lispro & 75% A10AD04000P5001X A* Patients with Type 2 diabetes Dose to be individualized. Insulin Lispro Protamine X whom experience The average daily insulin780 100 U/ml Suspension for hypoglycemia with the use of requirement is between 0.5 Injection in Prefilled human premixed insulin. to 1.0 units/kg body weight Syringe/Cartridge 50% Insulin Lispro & 50% A10AD04000P5002X A* Patients with Type 2 diabetes Dose to be individualized. Insulin Lispro Protamine X whom experience The average daily insulin781 100U/ml Suspension for hypoglycemia with the use of requirement is between 0.5 Injection in Prefilled human premixed insulin. to 1.0 units/kg body weights. Syringe/Cartridge Insulin Aspart 100 IU/ml A10AB05000P3001X Diabetic Type 1 and 2 in Dose to be individualised. Injection X patients that still experienced The average daily insulin782 A* hypoglycaemia with use of requirement is between 0.5 human insulin to 1.0 units/kg body weight783 Insulin Aspart 30% and A10AD05000P3001X A/KK Diabetic type 1 and 2 in Dose to be individualised. Protaminated Insulin Aspart X patients that still experienced The average daily insulin 70% 100 U/ml Injection hypoglycaemia with use of requirement is between 0.5 human insulin to 1.0 units/kg body weight i) Type 1 Diabetes patients on basal bolus regimen, whom experience hypoglycemia with Individualized dose given via conventional insulin, to be SC once or twice daily. used in combination with Initiate at a dose of 10IU or Insulin Detemir 100 IU/ml A10AE05000P5001X A/KK rapid or short-acting insulin. 0.1-0.2IU/kg. For twice daily784 Injection in Prefilled X ii) Type 2 Diabetes patients dosing, the evening dose can on oral anti-diabetics and be administered either with syringe/cartridge basal insulin regimen or the evening meal, at bedtime, basal bolus insulin regimen or 12 hours after the morning whom experience dose. hypoglycemia with conventional basal insulin. ADULT and CHILD over 6 years: individualised dose785 Insulin Glargine 300IU/3ml A10AE04000P5001X A/KK i) Diabetes mellitus type I in given by SC, once daily at Prefilled Pen for Injection X adults and child over 6 years the same time every day. ii) Diabetes mellitus type II in Adult patients who are insulin adult naïve may be initiated with 10IU daily. Glulisine should be given shortly (0-15 min) before or soon after meals. Apidra Treatment of adults, should be used in regimens786 Insulin Glulisine 100u/ml A10AB06000P5001X A* adolescents and children 6 that include an intermediate solution for injection in pre- X years or older with diabetes or long acting insulin or basal filled pen 3ml mellitus, where treatment insulin analogue and can be with insulin is required. used with oral hypoglycaemic agents. The dosage of Apidra should be individually adjusted.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 142 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) As initial therapy in children with Type 1 diabetes ii)Type 1 diabetes patients on basal bolus regimen, not controlled or experience hypoglycaemia with conventional insulin, to be used in combination with long-acting insulin Dose to be individualized. Insulin Lispro 100 IU/ml A10AB04000P5001X A* iii)Type 2 diabetes patients The average daily insulin787 Injection in Prefilled X on basal bolus or premixed requirement is between 0.5 regimen, not controlled or to 1.0 units/kg body weight, syringe/cartridge experience hypoglycaemia given within 15 minutes with conventional insulin, to before meal. be used in combination with intermediate-acting insulin or long-acting insulin iv)Patients with diabetes in pregnancy with poor postprandial control or experience hypoglycaemia with conventional short- acting insulin Dose to be individualised. The average daily insulin Insulin Recombinant requirement is between 0.3- 1.0 units/kg body weight/day.788 Neutral Human Short Acting A10AB01000P3001X B Diabetes mellitus Daily insulin requirement may 100 IU/ml Injection in 10ml X be higher in patients with vial insulin resistance, and lower in patients with residual, endogenous insulin production. Dose to be individualised. The average daily insulin requirement is between 0.3-789 Insulin Recombinant A10AB01000P5001X B Diabetes mellitus 1.0 units/kg body weight/day. Neutral Human Short-acting X Daily insulin requirement may 100IU/ml Penfill and Refill be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production. Insulin Recombinant Dose to be individualised.790 Synthetic Human A10AC01000P3001X B Diabetes mellitus The daily insulin requirement Intermediate-Acting X is usually between 0.3 and 100IU/ml in Vial for Injection 1.0IU/kg /day Dose to be individualised. The average daily insulin requirement is between 0.3-791 Insulin Recombinant A10AD01000P3001X B Diabetes mellitus 1.0 units/kg body weight/day. Synthetic Human Premixed X Daily insulin requirement may 100IU/ml in Vial for Injection be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 143 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Insulin dependent diabetes mellitus, non insulin Insulin Recombinant dependent diabetes unresponsive to treatment to Dose to be individualised.792 Synthetic Human, A10AC01000P5001X B diet or oral hypoglycaemics, The daily insulin requirement Intermediate-Acting 100 X hyperkalaemia to assure is usually between 0.3 and IU/ml Penfill and Refill proper utilisation of glucose 1.0IU/kg /day and reduce glucosuria in non diabetic patients receiving parenteral nutrition Insulin dependent diabetes mellitus, non insulin dependent diabetes793 Insulin Recombinant A10AD01000P5001X B unresponsive to treatment to Dose to be individualised. Synthetic Human, Premixed X diet or oral hypoglycaemics, The average daily insulin 100 IU/ml Penfill and Refill hyperkalaemia to assure requirement is between 0.5- proper utilisation of glucose 1.0 units/kg body weight and reduce glucosuria in non diabetic patients receiving parenteral nutrition i) Initial: 3 MIU SC daily. If intolerant, 1.5 MIU daily or 3 MIU 3 times a week or 1.5 MIU 3 times a week. Maintenance: 1.5-3 MIU SC 3 times a week ii) Patient > 18 years: 3 MIU daily (days 1-3), 6 MIU daily (days 4-6), 9 MIU daily (days 7-84) iii) Patient > 18 years: Initially794 Interferon Alfa - 2a 3 MIU L03AB04000P3001X A* For the treatment of escalating dose to 18-36 MIU Injection X i) Hairy cell leukaemia SC/IM for 10-12 weeks. ii) Chronic myelogenous Maintenance: up to 36 MIU 3 leukaemia times a week iii) AIDS related Kaposi's iv) 2.5-5 MIU/m2 SC 3 times Sarcoma a week for 4-6 months. iv) Chronic hepatitis B CHILD: up to 10 MIU/m2 v) Chronic hepatitis C vi) BSA v) Monotherapy: Initial: Advanced renal cell 3 - 6 MIU SC 3 times a week carcinoma for 6 months. Maintenance: 3 MIU 3 times a week for an additional 6 months. vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 MIU 3 times a week for 1 week, then 9 MIU 3 times a week for 1 week, then 18 MIU 3 times a week thereafter for 3-12 months SCUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 144 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 2 MIU SC or IM 3 times a For the treatment of week ii) Patient more than 18 i) Hairy cell leukaemia years: 3 - 9 MIU 3 - 5 times a ii) Chronic myelogenous week or daily depending on response leukaemia iii) Patient more than 18 years. Initially escalating795 Interferon Alfa-2b 18 MIU L03AB05000P5001X A iii) AIDS related Kaposi's dose to 18-36 MIU SC/IM for Multidose Injection Pen X sarcoma 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) Chronic hepatitis B iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: v) Chronic hepatitis C up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) Advanced renal cell vi) As an adjunct to cytotoxic chemotherapy: An escalating carcinoma dose of 3 million IU 3 times/week for 1 week, then For the treatment of 9 million IU 3 times/week for i) Hairy cell leukaemia 1 week, then 18 million IU 3 times/week thereafter for 3- ii) Chronic myelogenous 12 month SC or IM leukaemia i) 2 MIU SC or IM 3 times a796 Interferon Alfa-2b 30 MIU L03AB05000P5002X A iii) AIDS related Kaposi's week Multidose Injection Pen X sarcoma ii) Patient more than 18 iv) Chronic hepatitis B years: 3 - 9 MIU 3 - 5 times a week or daily depending on v) Chronic hepatitis C response vi) Advanced renal cell iii) Patient more than 18 years. Initially escalating carcinoma dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3- 12 month SC or IMUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 145 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 2 MIU SC or IM 3 times a For the treatment of week ii) Patient more than 18 i) Hairy cell leukaemia years: 3 - 9 MIU 3 - 5 times a ii) Chronic myelogenous week or daily depending on response leukaemia iii) Patient more than 18 years. Initially escalating797 Interferon Alpha - 2a 4.5 L03AB04000P3002X A* iii) AIDS related Kaposi's dose to 18-36 MIU SC/IM for MIU Injection X Sarcoma 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) Chronic hepatitis B iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: v) Chronic hepatitis C up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) Advanced renal cell vi) As an adjunct to cytotoxic chemotherapy: An escalating carcinoma dose of 3 million IU 3 times/week for 1 week, then For the treatment of 9 million IU 3 times/week for i) Hairy cell leukaemia 1 week, then 18 million IU 3 times/week thereafter for 3- ii) Chronic myelogenous 12 month SC or IM leukaemia i) 2 MIU/m2 SC or IM 3 times798 Interferon Alpha 2b 3 MIU L03AB05000P3001X A* iii) AIDS related Kaposi's a week Injection X sarcoma ii) 4 - 5 MIU/m2 SC daily. iv) Chronic hepatitis B Treatment must be discontinued after 8 to 12 v) Chronic hepatitis C weeks of treatment if at least a partial haematological vi) Advanced renal cell remission or a clinically carcinoma meaningful cytoreduction has not been achieved iii) Patient > 18 years : 30 MIU/m2 SC or IM three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment. iv) 5 MIU daily or 10 MIU three times a week for 16 weeks. CHILD: 3 MIU/m2 three times a week for the first week of therapy followed by dose escalation to 6 MIU/m2 (maximum of 10MIU) three times a week SC for a total duration of 16 to 24 weeks v) 3 MIU SC or IM 3 times a week.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 146 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Relapsing-remitting multiple sclerosis (RRMS): Reduction of frequency and degree of severity of clinical relapses in ambulatory patients characterized by at least two attacks of neurological dysfunction over Interferon beta -1b 250mcg L03AB08000P4001X the preceding two year 0.25 mg (8 MIU) by SC799 (8MIU) Injection X A* period, followed by complete injection every other day or incomplete recovery ii) Secondary progressive multiple sclerosis (SPMS):Reduction of frequency and severity of clinical relapses and for slowing the progression of disease Multiple sclerosis of the L03AB07000P5001X relapsing remitting type with800 Interferon Beta-1a 22 mcg X A* 2 or more relapses within the 22 mcg 3 times weekly last 2 years Multiple sclerosis of the L03AB07000P5002X relapsing remitting type with801 Interferon Beta-1a 44 mcg X A* 2 or more relapses within the 44 mcg 3 times weekly last 2 years802 Iodamide Injection V08AA03000P3001X A For hysterosalpingography According to the procedure X and route of administration803 Iodine and Potassium H03CA00200L9901X B i) Pre-operative treatment of i) 1 ml daily in divided doses Iodide Solution X thyrotoxicosis ii) 2 - 3 ml daily ii) Thyrotoxicosis crisis X-ray contrast medium for cardioangiography, cerebral angiography, peripheral arteriography, abdominal804 Iodixanol 320 mg I/ml V08AB09000P3001X A angiography, uroloraphy, Depending on type of Injection X venography, CT examination enhancement, lumbar, thoracic and cervical myelography X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT- enhancement. Lumbar, thoracic, cervical805 Iohexol Injection V08AB02000P3001X A myelography and computed Dose depending on the route X tomography of the basal and procedure cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tractUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 147 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY806 Iopamidol Injection V08AB04000P3001X i) Neuroradiology : For angiography and cardiac X A myeloradiculography, cases- dose depending on Iopromide 300mg injection cisternography and the route and procedure. For807 (623 mg of iopromide with V08AB05000P3001X A ventriculography selected vascular X A ii) Angiograph : cerebral examination - bottles of 30 ml 300 mg of iodine per mL) arteriography, thoracic and 100 ml; dose depending V08AB05000P3002X B aortography, abdominal on the route and procedure Iopromide 370mg injection X aortography,808 (769 mg of iopromide with angiocardiography, selective Dose depending on the route R03BB01320A3001X visceral arteriography, and procedure 370 mg of iodine per mL) X peripheral arteriography, venography, digital Dose depending on the route Ipratropium Bromide subtraction angiography and procedure809 0.0125% Nebulising (DSA), DSA of cerebral arteries, DSA of peripheral ADULT: 500 mcg up to 4 Solution (125 mcg/ml) arteries, DSA of abdominal times daily. CHILD 5 - 12 arteries years : 125 - 250 mcg up to 4 iii) Urography : intravenous times daily, 12 years : 250 - urography iv) Contrast 500 mcg up to 4 times daily enhancement in CT Scanning, arthrography, fistulography i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt Only for treatment of: i) Patients with ischaemic heart disease who develop extrasystole with salbutamol or terbutaline ii) Patients with chronic bronchitis who have airway obstruction and who do not respond to salbutamol or terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary diseaseUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 148 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Only for treatment of: i) Patients with ischaemic heart disease who develop extrasystole with salbutamol810 Ipratropium Bromide R03BB01320A3002X B or terbutaline ADULT: 500 mcg up to 4 0.025% Nebulising Solution X ii) Patients with chronic times daily. CHILD 5 - 12 (250 mcg/ml) bronchitis who have airway years : 125 - 250 mcg up to 4 obstruction and who do not times daily, 12 years : 250 - respond to salbutamol or 500 mcg up to 4 times daily terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary disease Acute attacks: 1 unit dose vial. In severe cases not811 Ipratropium Bromide 0.5 mg R03AK04320A3001X B Management of reversible relieved by 1 unit dose vial, 2 and Salbutamol 2.5 mg per X bronchospasm associated unit dose vials may require, UDV with obstructive airway patient should consult a diseases doctor immediately. Maintenance : 1 unit dose vial 3 - 4 times daily ADULT & CHILD more than 6 years; Acute asthma 2 puffs. Management of symptoms in Severe cases: if breathing chronic obstructive airway has not noticeably improved Ipratropium Bromide 20 R03AK03986A2101X disorders with reversible after 5 mins, 2 further puffs X812 mcg and Fenoterol 50 B bronchospasm such as may be taken. Intermittent mcg/dose Inhaler bronchial asthma and chronic and long-term treatment 1-2 bronchitis with or without puffs for each administration, emphysema up to max 8 puffs/day (average: 1-2 puffs three times daily) ADULT and ELDERLY: 2 Management of reversible inhalations 4 times daily. Ipratropium Bromide 20 R03AK04320A1001X B bronchospasm associated Maximum: 12 inhalations813 mcg and Salbutamol base X with obstructive airway daily. CHILD under 12 years diseases not recommended 100 mcg/dose Inhalation Only for treatment of :814 Ipratropium Bromide 20 R03BB01320A1001X B i) Patients with chronic 20 - 40 mcg 3 - 4 times daily. mcg/dose Inhalation X bronchitis who have airway In the early treatment, up to obstruction and who do not 80 mcg 3 - 4 times daily. respond to Salbutamol or CHILD up to 6 years : 20 Terbutaline mcg 3 times daily, 6 - 12 ii) Patients with ischaemic years : 20 - 40 mcg 3 times heart disease who develop daily extrasystole with Salbutamol or Terbutaline Irbesartan 150 mg and C09DA04000T1003X A/KK Hypertension in patients who 1 tablet daily815 Hydrochlorothiazide 12.5 X cannot tolerate ACE inhibitors because of cough mg Tablet C09CA04000T1001X Hypertension, diabetic X nephropathy (in patients who816 Irbesartan 150 mg Tablet A/KK cannot tolerate ACE 150 mg to 300 mg daily inhibitors because of cough)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 149 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Irbesartan 300 mg & C09DA04000T1001X A/KK Hypertension in patients who 1 tablet daily817 Hydrochlorothiazide 12.5 X cannot tolerate ACE inhibitors because of cough mg Tablet Hypertension, diabetic C09CA04000T1002X nephropathy (in patients who818 Irbesartan 300 mg Tablet X A/KK cannot tolerate ACE 150 mg to 300 mg daily inhibitors because of cough) Only for patients with819 Irinotecan HCl Trihydrate 20 L01XX19110P3002X A* colorectal cancer who: In combination therapy (for mg/ml Injection X i) have relapsed within 6 previously untreated months after the end of patients): 180 mg/m2 once adjuvant chemotherapy with every 2 weeks as an IV 5-fluorouracil-based regime infusion over 90 mins ii) have progressive disease followed by infusion with despite 5-fluorouracil folinic acid and 5-fluorouracil. chemotherapy for advanced In monotherapy (for disease previously treated patients): iii) good performance status 350 mg/m2 administered as (WHO of 2 or less) The an intravenous infusion over treatment must be given in a 90 minutes period once every tertiary oncology centre or 3 weeks have clearance in writing by an oncologist Only for patients with820 Irinotecan HCl Trihydrate 40 L01XX19110P3001X A* colorectal cancer who: In combination therapy (for mg/2 ml Injection X i) have relapsed within 6 previously untreated months after the end of patients): 180 mg/m2 once adjuvant chemotherapy with every 2 weeks as an IV 5-fluorouracil-based regime infusion over 90 mins ii) have progressive disease followed by infusion with despite 5-fluorouracil folinic acid and 5-fluorouracil. chemotherapy for advanced In monotherapy (for disease previously treated patients): iii) good performance status 350 mg/m2 administered as (WHO of 2 or less) The an intravenous infusion over treatment must be given in a 90 minutes period once every tertiary oncology centre or 3 weeks have clearance in writing by an oncologist Dosage and duration of therapy are dependent upon the extent of iron deficiency. Manifest iron deficiency: 1 chewable tablet two to three Iron (III)-hydroxide Treatment of latent and times daily until a manifest iron deficiency and normalization of the821 polymaltose complex (IPC) B03AD04250T2001X A/KK prevention of iron and folic hemoglobin value is 100mg iron and 0.35mg X acid deficiency before, during achieved. Afterwards the after pregnancy (during therapy should be continued folic acid chewable tablet lactation) with 1 chewable tablet daily at least until the end of pregnancy to replenish the iron stores. Latent iron deficiency and prevention of iron and folic acid deficiency: 1 chewable tablet dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 150 / 314